

複層カーボンナノチューブ（MWCNT）の
ラットを用いた吸入によるがん原性試験報告書

試験番号：0800

TABLES

TABLES

TABLE A	CONCENTRATIONS OF MULTI-WALL CARBON NANOTUBE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY
TABLE B	COLLECTION CUMULATIVE RATE
TABLE C1	SURVIVAL ANIMAL NUMBERS: MALE
TABLE C2	SURVIVAL ANIMAL NUMBERS: FEMALE
TABLE D1	CLINICAL OBSERVATION: MALE
TABLE D2	CLINICAL OBSERVATION: FEMALE
TABLE E1	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE
TABLE E2	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE
TABLE E3	BODY WEIGHT CHANGES: MALE
TABLE E4	BODY WEIGHT CHANGES: FEMALE
TABLE F1	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE
TABLE F2	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE
TABLE F3	FOOD CONSUMPTION CHANGES: MALE
TABLE F4	FOOD CONSUMPTION CHANGES: FEMALE
TABLE G1	HEMATOLOGY: MALE
TABLE G2	HEMATOLOGY: FEMALE

TABLES (CONTINUED)

TABLE	H1	BIOCHEMISTRY: MALE
TABLE	H2	BIOCHEMISTRY: FEMALE
TABLE	I1	URINALYSIS: MALE
TABLE	I2	URINALYSIS: FEMALE
TABLE	J1	GROSS FINDINGS: MALE
TABLE	J2	GROSS FINDINGS: FEMALE
TABLE	K1	ORGAN WEIGHT, ABSOLUTE: MALE
TABLE	K2	ORGAN WEIGHT, ABSOLUTE: FEMALE
TABLE	L1	ORGAN WEIGHT, RELATIVE: MALE
TABLE	L2	ORGAN WEIGHT, RELATIVE: FEMALE
TABLE	M1	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE
TABLE	M2	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE
TABLE	N1	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE
TABLE	N2	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE
TABLE	O1	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j MALE RATS
TABLE	O2	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j FEMALE RATS

TABLES (CONTINUED)

TABLE	P1	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE
TABLE	P2	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE
TABLE	Q1	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: MALE
TABLE	Q2	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: FEMALE
TABLE	R1	CAUSE OF DEATH: MALE
TABLE	R2	CAUSE OF DEATH: FEMALE

TABLE A

CONCENTRATIONS OF MULTI-WALL CARBON NANOTUBE
IN THE INHALATION CHAMBER
OF THE 2-YEAR INHALATION STUDY

TABLE A CONCENTRATIONS OF MULTI-WALL CARBON NANOTUBE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

Group Name	Concentration(mg/m ³) Mean ± S.D.
Control	0.000 ± 0.000
0.02 mg/m ³	0.020 ± 0.001
0.2 mg/m ³	0.204 ± 0.014
2 mg/m ³	2.018 ± 0.069

TABLE B

COLLECTION CUMULATIVE RATE

TABLE B COLLECTION CUMULATIVE RATE

Administration 1 Week

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.025	5.00	100	0.028	4.05	100	0.018	2.06	100
1	10	0.026	5.20	95.00	0.018	2.60	95.95	0.012	1.37	97.94
2	5.6	0.079	15.80	89.80	0.127	18.35	93.35	0.164	18.79	96.56
3	3.2	0.121	24.20	74.00	0.194	28.03	75.00	0.247	28.29	77.78
4	1.8	0.095	19.00	49.80	0.128	18.50	46.97	0.208	23.83	49.48
5	1.0	0.066	13.20	30.80	0.096	13.87	28.47	0.108	12.37	25.66
6	0.56	0.042	8.40	17.60	0.064	9.25	14.60	0.051	5.84	13.29
7	0.32	0.027	5.40	9.20	0.021	3.03	5.35	0.034	3.89	7.45
8	0.18	0.012	2.40	3.80	0.011	1.59	2.31	0.026	2.98	3.55
9	0.10	0.005	1.00	1.40	0.003	0.43	0.72	0.004	0.46	0.57
10	0.056	0.002	0.40	0.40	0.001	0.14	0.29	0.001	0.11	0.11
11	0.032	0.000	0.00	0.00	0.001	0.14	0.14	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.500	100	-	0.692	100	-	0.873	100	-

Administration 14 Weeks

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.020	2.80	100	0.031	4.87	100	0.027	4.32	100
1	10	0.018	2.52	97.20	0.023	3.61	95.13	0.016	2.56	95.68
2	5.6	0.135	18.88	94.69	0.078	12.24	91.52	0.126	20.16	93.12
3	3.2	0.185	25.87	75.80	0.158	24.80	79.28	0.148	23.68	72.96
4	1.8	0.151	21.12	49.93	0.125	19.62	54.47	0.120	19.20	49.28
5	1.0	0.105	14.69	28.81	0.094	14.76	34.85	0.093	14.88	30.08
6	0.56	0.045	6.29	14.13	0.067	10.52	20.09	0.047	7.52	15.20
7	0.32	0.028	3.92	7.83	0.040	6.28	9.58	0.025	4.00	7.68
8	0.18	0.017	2.38	3.92	0.015	2.35	3.30	0.014	2.24	3.68
9	0.10	0.010	1.40	1.54	0.004	0.63	0.94	0.007	1.12	1.44
10	0.056	0.001	0.14	0.14	0.002	0.31	0.31	0.002	0.32	0.32
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.715	100	-	0.637	100	-	0.625	100	-

TABLE B COLLECTION CUMULATIVE RATE (CONTINUED)

Administration 27 Weeks

Stage No. (μm)		0.02 mg/m ³			0.2 mg/m ³			2 mg/m ³		
		Flow : 30 ℓ /min		Time : 1800min	Flow : 30 ℓ /min		Time : 180min	Flow : 30 ℓ /min		Time : 18min
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.028	3.93	100	0.037	4.92	100	0.030	3.44	100
1	10	0.018	2.53	96.07	0.023	3.06	95.08	0.047	5.40	96.56
2	5.6	0.127	17.84	93.54	0.135	17.95	92.02	0.137	15.73	91.16
3	3.2	0.194	27.25	75.70	0.189	25.13	74.07	0.196	22.50	75.43
4	1.8	0.128	17.98	48.46	0.129	17.15	48.94	0.156	17.91	52.93
5	1.0	0.096	13.48	30.48	0.104	13.83	31.78	0.115	13.20	35.02
6	0.56	0.064	8.99	16.99	0.068	9.04	17.95	0.093	10.68	21.81
7	0.32	0.041	5.76	8.01	0.034	4.52	8.91	0.060	6.89	11.14
8	0.18	0.011	1.54	2.25	0.025	3.32	4.39	0.031	3.56	4.25
9	0.10	0.003	0.42	0.70	0.005	0.66	1.06	0.004	0.46	0.69
10	0.056	0.001	0.14	0.28	0.003	0.40	0.40	0.002	0.23	0.23
11	0.032	0.001	0.14	0.14	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.712	100	-	0.752	100	-	0.871	100	-

Administration 40 Weeks

Stage No. (μm)		0.02 mg/m ³			0.2 mg/m ³			2 mg/m ³		
		Flow : 30 ℓ /min		Time : 1800min	Flow : 30 ℓ /min		Time : 180min	Flow : 30 ℓ /min		Time : 18min
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.022	2.60	100	0.024	3.65	100	0.029	3.57	100
1	10	0.054	6.38	97.40	0.012	1.83	96.35	0.022	2.71	96.43
2	5.6	0.173	20.43	91.03	0.119	18.11	94.52	0.125	15.39	93.72
3	3.2	0.212	25.03	70.60	0.186	28.31	76.41	0.214	26.35	78.33
4	1.8	0.156	18.42	45.57	0.133	20.24	48.10	0.144	17.73	51.97
5	1.0	0.101	11.92	27.15	0.077	11.72	27.85	0.103	12.68	34.24
6	0.56	0.062	7.32	15.23	0.056	8.52	16.13	0.078	9.61	21.55
7	0.32	0.036	4.25	7.91	0.026	3.96	7.61	0.062	7.64	11.95
8	0.18	0.017	2.01	3.66	0.015	2.28	3.65	0.032	3.94	4.31
9	0.10	0.011	1.30	1.65	0.007	1.07	1.37	0.003	0.37	0.37
10	0.056	0.003	0.35	0.35	0.002	0.30	0.30	0.000	0.00	0.00
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.847	100	-	0.657	100	-	0.812	100	-

TABLE B COLLECTION CUMULATIVE RATE (CONTINUED)

Administration 53 Weeks

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.063	7.74	100	0.022	3.69	100	0.031	4.93	100
1	10	0.032	3.93	92.26	0.021	3.52	96.31	0.018	2.86	95.07
2	5.6	0.133	16.34	88.33	0.126	21.14	92.79	0.118	18.76	92.21
3	3.2	0.164	20.15	71.99	0.162	27.18	71.64	0.170	27.03	73.45
4	1.8	0.147	18.06	51.84	0.112	18.79	44.46	0.132	20.99	46.42
5	1.0	0.105	12.90	33.78	0.084	14.09	25.67	0.075	11.92	25.44
6	0.56	0.084	10.32	20.88	0.040	6.71	11.58	0.049	7.79	13.51
7	0.32	0.052	6.39	10.57	0.014	2.35	4.87	0.021	3.34	5.72
8	0.18	0.025	3.07	4.18	0.008	1.34	2.52	0.010	1.59	2.38
9	0.10	0.009	1.11	1.11	0.004	0.67	1.17	0.002	0.32	0.79
10	0.056	0.000	0.00	0.00	0.003	0.50	0.50	0.003	0.48	0.48
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.814	100	-	0.596	100	-	0.629	100	-

Administration 66 Weeks

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.021	2.92	100	0.025	3.52	100	0.030	4.25	100
1	10	0.019	2.65	97.08	0.024	3.38	96.48	0.020	2.83	95.75
2	5.6	0.135	18.80	94.43	0.133	18.71	93.11	0.128	18.13	92.92
3	3.2	0.184	25.63	75.63	0.196	27.57	74.40	0.196	27.76	74.79
4	1.8	0.151	21.03	50.00	0.153	21.52	46.84	0.163	23.09	47.03
5	1.0	0.105	14.62	28.97	0.081	11.39	25.32	0.078	11.05	23.94
6	0.56	0.045	6.27	14.35	0.057	8.02	13.92	0.056	7.93	12.89
7	0.32	0.028	3.90	8.08	0.020	2.81	5.91	0.021	2.97	4.96
8	0.18	0.017	2.37	4.18	0.013	1.83	3.09	0.008	1.13	1.98
9	0.10	0.009	1.25	1.81	0.005	0.70	1.27	0.004	0.57	0.85
10	0.056	0.004	0.56	0.56	0.004	0.56	0.56	0.002	0.28	0.28
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.718	100	-	0.711	100	-	0.706	100	-

TABLE B COLLECTION CUMULATIVE RATE (CONTINUED)

Administration 79 Weeks

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.020	3.27	100	0.017	2.75	100	0.041	4.24	100
1	10	0.017	2.78	96.73	0.017	2.75	97.25	0.025	2.58	95.76
2	5.6	0.135	22.09	93.94	0.116	18.77	94.50	0.180	18.60	93.18
3	3.2	0.185	30.28	71.85	0.160	25.89	75.73	0.250	25.83	74.59
4	1.8	0.105	17.18	41.57	0.144	23.30	49.84	0.208	21.49	48.76
5	1.0	0.045	7.36	24.39	0.073	11.81	26.54	0.117	12.09	27.27
6	0.56	0.046	7.53	17.02	0.053	8.58	14.72	0.099	10.23	15.19
7	0.32	0.029	4.75	9.49	0.019	3.07	6.15	0.028	2.89	4.96
8	0.18	0.017	2.78	4.75	0.008	1.29	3.07	0.009	0.93	2.07
9	0.10	0.010	1.64	1.96	0.007	1.13	1.78	0.008	0.83	1.14
10	0.056	0.002	0.33	0.33	0.004	0.65	0.65	0.003	0.31	0.31
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.611	100	-	0.618	100	-	0.968	100	-

Administration 92 Weeks

Stage No. (μm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.017	2.66	100	0.019	3.47	100	0.032	4.64	100
1	10	0.066	10.34	97.34	0.035	6.40	96.53	0.020	2.90	95.36
2	5.6	0.121	18.97	86.99	0.137	25.05	90.13	0.116	16.81	92.46
3	3.2	0.153	23.98	68.03	0.108	19.74	65.08	0.167	24.20	75.65
4	1.8	0.106	16.61	44.04	0.089	16.27	45.34	0.167	24.20	51.45
5	1.0	0.076	11.91	27.43	0.071	12.98	29.07	0.079	11.45	27.25
6	0.56	0.039	6.11	15.52	0.037	6.76	16.09	0.073	10.58	15.80
7	0.32	0.024	3.76	9.40	0.021	3.84	9.32	0.021	3.04	5.22
8	0.18	0.023	3.61	5.64	0.017	3.11	5.48	0.010	1.45	2.17
9	0.10	0.010	1.57	2.04	0.011	2.01	2.38	0.001	0.14	0.72
10	0.056	0.003	0.47	0.47	0.002	0.37	0.37	0.004	0.58	0.58
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.638	100	-	0.547	100	-	0.690	100	-

TABLE B COLLECTION CUMULATIVE RATE (CONTINUED)

Administration 102 Weeks

Stage No. (µm)		0.02 mg/m ³ Flow : 30 ℓ /min Time : 1800min			0.2 mg/m ³ Flow : 30 ℓ /min Time : 180min			2 mg/m ³ Flow : 30 ℓ /min Time : 18min		
		Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)	Weight (mg)	Mass Fraction (%)	Cumulative Rate (%)
0	18	0.038	5.37	100	0.029	4.01	100	0.024	3.45	100
1	10	0.022	3.11	94.63	0.013	1.80	95.99	0.014	2.01	96.55
2	5.6	0.119	16.83	91.51	0.099	13.67	94.20	0.144	20.69	94.54
3	3.2	0.193	27.30	74.68	0.132	18.23	80.52	0.197	28.30	73.85
4	1.8	0.145	20.51	47.38	0.191	26.38	62.29	0.144	20.69	45.55
5	1.0	0.089	12.59	26.87	0.141	19.48	35.91	0.078	11.21	24.86
6	0.56	0.053	7.50	14.29	0.074	10.22	16.44	0.045	6.47	13.65
7	0.32	0.025	3.54	6.79	0.032	4.42	6.22	0.025	3.59	7.18
8	0.18	0.013	1.84	3.25	0.008	1.10	1.80	0.013	1.87	3.59
9	0.10	0.007	0.99	1.41	0.004	0.55	0.69	0.010	1.44	1.72
10	0.056	0.003	0.42	0.42	0.001	0.14	0.14	0.002	0.29	0.29
11	0.032	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
12	0.018	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
13	0.010	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Final	0.005	0.000	0.00	0.00	0.000	0.00	0.00	0.000	0.00	0.00
Total		0.707	100	-	0.724	100	-	0.696	100	-

TABLE C1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0

Number of survival/ Number of effective animals
 Survival rate(%)

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0
2mg/m3	50	50/50 100.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0

Number of survival/ Number of effective animals
 Survival rate(%)

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.02mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0
0.2mg/m3	50	48/50 96.0	48/50 96.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0
2mg/m3	50	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	47/50 94.0	47/50 94.0
0.02mg/m3	50	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0
0.2mg/m3	50	46/50 92.0	46/50 92.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0
2mg/m3	50	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0	42/50 84.0
0.02mg/m3	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0
0.2mg/m3	50	42/50 84.0	42/50 84.0	42/50 84.0	42/50 84.0	42/50 84.0	42/50 84.0	41/50 82.0	41/50 82.0	41/50 82.0	41/50 82.0	41/50 82.0	40/50 80.0	39/50 78.0	39/50 78.0
2mg/m3	50	46/50 92.0	45/50 90.0	45/50 90.0	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)						
		98	99	100	101	102	103	104
Control	50	41/50 82.0	40/50 80.0	39/50 78.0	36/50 72.0	36/50 72.0	36/50 72.0	36/50 72.0
0.02mg/m3	50	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0
0.2mg/m3	50	39/50 78.0	39/50 78.0	39/50 78.0	39/50 78.0	39/50 78.0	39/50 78.0	38/50 76.0
2mg/m3	50	42/50 84.0	42/50 84.0	40/50 80.0	40/50 80.0	38/50 76.0	38/50 76.0	37/50 74.0
		Number of survival/ Number of effective animals Survival rate(%)						

TABLE C2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0
0.2mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
2mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.02mg/m3	50	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0
0.2mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
2mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0
0.02mg/m3	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0
0.2mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0
2mg/m3	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0
0.02mg/m3	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0
0.2mg/m3	50	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	45/50 90.0	45/50 90.0	44/50 88.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0	42/50 84.0
2mg/m3	50	45/50 90.0	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	41/50 82.0	41/50 82.0	41/50 82.0	41/50 82.0	41/50 82.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)						
		98	99	100	101	102	103	104
Control	50	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0
0.02mg/m3	50	42/50 84.0	41/50 82.0	40/50 80.0	40/50 80.0	38/50 76.0	36/50 72.0	34/50 68.0
0.2mg/m3	50	42/50 84.0	42/50 84.0	42/50 84.0	41/50 82.0	40/50 80.0	40/50 80.0	39/50 78.0
2mg/m3	50	40/50 80.0	38/50 76.0	38/50 76.0	38/50 76.0	36/50 72.0	36/50 72.0	36/50 72.0
		Number of survival/ Number of effective animals Survival rate(%)						

TABLE D1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	2	2
	2mg/m3	1	1	2	2	2	2	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	2	2
	0.2mg/m3	2	4	4	4	4	4	4	4	4	4	4	4	4	4
	2mg/m3	2	2	2	2	2	2	2	2	2	3	3	3	3	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	1	1	1	1	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	0.02mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	3
	0.2mg/m3	4	5	5	5	5	5	5	5	5	5	5	5	6	6
	2mg/m3	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	1	1	1	1	2	2	2	2	2
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	2	2	2	2	3	4	4	4	5	5	5	5	5	6
	0.02mg/m3	3	3	3	3	3	3	3	3	3	3	3	3	3	4
	0.2mg/m3	6	6	6	6	6	7	7	7	7	7	8	9	9	9
	2mg/m3	5	5	5	5	5	5	5	6	6	6	6	6	6	7
MORIBUND SACRIFICE	Control	1	1	1	2	2	2	2	2	2	2	2	3	3	3
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	2	2
	0.2mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	2mg/m3	0	0	0	1	1	1	1	1	1	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	1
SOILED	Control	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	7	8	10	10	10	10
	0.02mg/m3	4	4	5	5	5	6
	0.2mg/m3	9	9	9	9	9	9
	2mg/m3	7	7	7	8	8	9
MORIBUND SACRIFICE	Control	3	3	4	4	4	4
	0.02mg/m3	2	2	2	2	2	2
	0.2mg/m3	2	2	2	2	2	2
	2mg/m3	1	3	3	4	4	4
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	2	1	1	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
WASTING	Control	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	1
	0.2mg/m3	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1
SOILED	Control	0	0	0	0	1	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	0	0	0	0	0
FROG BELLY	Control	1	1	0	0	0	0
	0.02mg/m3	0	0	0	0	0	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day				32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		29-7	30-7	31-7												
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1	
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	1	1	1	1	1	1	1	1	1	1	1	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	2	2	2	2	2	2	2	2	2	2	2	2
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0	1	1	1	2	1	1	2	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	3	3	3	3	3	3	3	3	4	4	4	4	4	4
	0.02mg/m3	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	1	1	1	1	1	1	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	1	1	1	1	1	1	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	2	2	2	2	2	2	2	3	2	2	4	4	4
	0.02mg/m3	2	2	2	2	3	3	3	3	3	3	3	3	3	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	2mg/m3	2	2	2	2	2	2	2	2	3	4	3	3	4	3
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	0.02mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	1	1	1	2	2	2	2	2	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	1	1	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	4	4	4	3	3	3	5	6	6	6	6	6
	0.02mg/m3	2	4	5	6	6	6	6	7	8	8	9	9	8	7
	0.2mg/m3	1	2	1	2	2	2	2	3	3	3	4	3	5	5
	2mg/m3	3	3	3	3	3	3	3	2	2	2	2	2	3	3
INTERNAL MASS	Control	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
SOILED PERI-GENITALIA	Control	0	0	0	0	1	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	0	0	0
EXOPHTHALMOS	Control	0	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
CATARACT	Control	5	5	4	4	4	4
	0.02mg/m3	2	2	2	2	2	1
	0.2mg/m3	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	1
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
EXTERNAL MASS	Control	7	6	5	5	6	7
	0.02mg/m3	8	8	7	7	7	9
	0.2mg/m3	7	8	8	8	9	12
	2mg/m3	3	4	5	5	5	6
INTERNAL MASS	Control	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	1
	0.2mg/m3	0	2	2	2	2	3
	2mg/m3	0	0	0	0	0	1
M.PERI-MOUTH	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	1	1
	2mg/m3	0	0	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	1	1	1	2	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 22

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	1	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	1
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	0	1	0	0	0	0	0	0	0	0	0	0	1	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	2	2	2	2	2	1	1	1	2	3	3	3	3	3
	0.02mg/m3	0	2	2	2	2	2	2	2	2	2	1	1	1	0
	0.2mg/m3	0	0	0	1	1	1	1	1	1	1	1	1	1	2
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	2	2
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.02mg/m3	0	0	1	1	1	1	1	2	2	2	2	2	2	2
	0.2mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	2	2
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	1	1	1	1	1	2	2	2	2	2	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
M. EAR	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0
M. BREAST	Control	3	3	3	3	4	4
	0.02mg/m3	1	1	1	0	0	0
	0.2mg/m3	3	3	3	3	3	5
	2mg/m3	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	1	1
	0.02mg/m3	2	2	1	2	2	2
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	2	3	3	3	3	3
M. ANTERIOR DORSUM	Control	2	2	2	2	1	2
	0.02mg/m3	2	2	2	2	2	2
	0.2mg/m3	2	2	2	2	2	2
	2mg/m3	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0
	0.02mg/m3	2	2	2	2	2	2
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 27

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 28

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 29

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 30

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.02mg/m3	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 31

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.HINDLIMB	Control	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	3	3	2	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	1	1	2	1	1	1	1	2	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	1	2	1	1	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	2mg/m3	0	1	1	0	0	0	0	0	0	1	1	2	2	1
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	1	0	0	0	0	0	1	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : MALE

PAGE : 32

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
M.HINDLIMB	Control	2	1	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	1	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
IRREGULAR BREATHING	Control	1	1	1	1	1	2
	0.02mg/m3	0	0	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1
TACHYPNEA	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	1
	2mg/m3	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0

TABLE D2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 33

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 34

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	2	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2mg/m3	1	1	1	1	1	2	2	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	1	0	0	0	0	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	1

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

PAGE : 35

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.02mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 36

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	1	1	0	0	0	0	0	0	0	0	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	2	2	2	2	2	2	2	2	2	3	3	3	3	3
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 37

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	2	2	2	2	2	2	3	3	3
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	1	0	0	0	0	0	0	1	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	0	0	0	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	0.2mg/m3	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 38

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	0	0	0	0	0	0	0	0	0	1	2	2	2	2
	0.02mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	2mg/m3	3	3	3	3	3	3	3	3	3	4	4	4	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	1	2	2	2	2	2	2	2
	2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	0.2mg/m3	2	2	2	2	2	2	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 39

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	2	2	2	2	2	2	2	2	2	3	3	3	3	
	0.02mg/m3	2	2	2	2	3	3	4	4	4	4	4	4	5	5
	0.2mg/m3	2	2	2	2	2	2	2	2	3	3	3	3	3	3
	2mg/m3	4	5	5	5	5	5	5	5	6	6	6	6	6	7
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	2	3	3	3	3	3	3	3
	0.02mg/m3	1	1	1	1	1	2	3	3	3	3	3	3	3	3
	0.2mg/m3	2	2	2	2	3	3	4	4	4	4	4	5	5	5
	2mg/m3	1	1	1	1	1	1	1	2	3	3	3	3	3	3
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	1	0	0	0	0	0	1	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.02mg/m3	3	3	3	3	3	3	3	2	2	2	2	2	2	2
	0.2mg/m3	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 40

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	3	3	3	3	3	4
	0.02mg/m3	6	7	7	7	8	9
	0.2mg/m3	3	3	3	3	3	3
	2mg/m3	7	7	7	9	9	9
MORIBUND SACRIFICE	Control	4	4	4	4	4	4
	0.02mg/m3	3	3	3	5	6	7
	0.2mg/m3	5	5	6	7	7	8
	2mg/m3	5	5	5	5	5	5
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	1
SOILED	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	1	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	1
SOILED PERI-GENITALIA	Control	1	1	1	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	1	1	0	0	0	0
	2mg/m3	0	0	0	0	0	1
CATARACT	Control	1	2	2	2	2	2
	0.02mg/m3	2	2	2	2	2	2
	0.2mg/m3	2	2	2	2	2	2
	2mg/m3	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

PAGE : 41

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 42

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 43

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 44

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 45

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	2	2	2	2	1	1	1	1
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	2mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	1
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 46

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	3	3	4	4
	0.2mg/m3	2	2	2	2	2	2	2	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	2	2	2	3	3	4	4	4	4	4
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	1
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	1	1	2	2	2
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 47

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
CORNEAL EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	2	3	4	4	4	5	5	5
	0.02mg/m3	4	5	5	5	5	5	5	4	5	5	5	6	6	6
	0.2mg/m3	2	2	2	2	3	3	3	4	4	5	6	6	6	6
	2mg/m3	4	4	4	4	4	5	5	5	4	5	5	5	7	7
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	2
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.BREAST	Control	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	0.02mg/m3	2	3	3	3	3	3	3	3	4	4	4	4	5	5
	0.2mg/m3	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	2mg/m3	0	0	0	0	0	1	1	1	1	2	2	2	3	3

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 48

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
CORNEAL EDEMA	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	1
EXTERNAL MASS	Control	5	5	5	5	5	7
	0.02mg/m3	5	4	4	4	4	4
	0.2mg/m3	7	7	8	7	7	9
	2mg/m3	7	7	7	6	6	7
INTERNAL MASS	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1
M. NOSE	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	1
M. PERI -MOUTH	Control	0	0	0	0	0	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1
	2mg/m3	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	1
	2mg/m3	1	1	1	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1
M. BREAST	Control	1	1	1	1	1	1
	0.02mg/m3	5	4	4	4	4	4
	0.2mg/m3	3	3	2	1	1	1
	2mg/m3	3	3	3	3	3	3

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 49

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 50

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 51

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 52

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 53

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 54

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	1	1	1	1	1	1	1	0	0	0	0	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	1	1	1	1	1	1	1	1	1	1
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	1	1	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

PAGE : 55

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M. ABDOMEN	Control	1	1	1	1	1	1	1	1	1	1	1	2	2	2
	0.02mg/m3	1	1	1	1	1	1	1	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	1	1	1	1	1	1	1	1	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	1	2	2	2	2	2	2
	0.02mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	1	2	2	2	2
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
ANEMIA	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.2mg/m3	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	1	0	0	0	0	0	1
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.2mg/m3	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	1	1	1	0	0	0	0	0	0	0
	0.02mg/m3	0	0	0	1	0	0	0	0	0	0	0	0	0	1
	0.2mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0	1	1	0	0	0	1	1	0

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRij[F344/DuCrj]
 REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
 ALL ANIMALS

SEX : FEMALE

PAGE : 56

Clinical sign	Group Name	Administration Week-day					
		99-7	100-7	101-7	102-7	103-7	104-7
M. ABDOMEN	Control	2	2	2	2	2	2
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	2	2	4	4	4	4
	2mg/m3	0	0	0	0	0	0
M. ANTERIOR.DORSUM	Control	0	0	0	0	0	1
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
M. GENITALIA	Control	2	2	2	2	2	2
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	2	2	2	2	2	3
	2mg/m3	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0
	0.02mg/m3	1	0	0	1	0	0
	0.2mg/m3	0	0	0	0	1	0
	2mg/m3	0	0	0	0	1	1
HEMORRHAGE	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0
	0.02mg/m3	0	0	0	0	0	0
	0.2mg/m3	0	0	0	0	0	0
	2mg/m3	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0
	0.02mg/m3	1	0	0	0	0	0
	0.2mg/m3	0	1	1	0	0	0
	2mg/m3	0	0	0	0	0	1

TABLE E1

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control		0.02mg/m3		0.2mg/m3		2mg/m3				
	Av.Wt.	No.of Surviv.<50>	Av.Wt.	% of cont.<50>	No.of Surviv.	Av.Wt.	% of cont.<50>	No.of Surviv.	Av.Wt.	% of cont.<50>	No.of Surviv.
0	120 (50)	50/50	120 (50)	100	50/50	120 (50)	100	50/50	120 (50)	100	50/50
1	147 (50)	50/50	148 (50)	101	50/50	148 (50)	101	50/50	146 (50)	99	50/50
2	178 (50)	50/50	178 (50)	100	50/50	178 (50)	100	50/50	176 (50)	99	50/50
3	202 (50)	50/50	202 (50)	100	50/50	202 (50)	100	50/50	200 (50)	99	50/50
4	222 (50)	50/50	223 (50)	100	50/50	223 (50)	100	50/50	222 (50)	100	50/50
5	239 (50)	50/50	239 (50)	100	50/50	239 (50)	100	50/50	239 (50)	100	50/50
6	252 (50)	50/50	253 (50)	100	50/50	254 (50)	101	50/50	254 (50)	101	50/50
7	264 (50)	50/50	262 (50)	99	50/50	264 (50)	100	50/50	266 (50)	101	50/50
8	275 (50)	50/50	275 (50)	100	50/50	276 (50)	100	50/50	279 (50)	101	50/50
9	285 (50)	50/50	286 (50)	100	50/50	286 (50)	100	50/50	290 (50)	102	50/50
10	295 (50)	50/50	296 (50)	100	50/50	295 (50)	100	50/50	299 (50)	101	50/50
11	303 (50)	50/50	303 (50)	100	50/50	303 (50)	100	50/50	307 (50)	101	50/50
12	310 (50)	50/50	311 (50)	100	50/50	311 (50)	100	50/50	314 (50)	101	50/50
13	316 (50)	50/50	318 (50)	101	50/50	317 (50)	100	50/50	322 (50)	102	50/50
14	322 (50)	50/50	324 (50)	101	50/50	323 (50)	100	50/50	329 (50)	102	50/50
18	343 (49)	49/50	344 (50)	100	50/50	343 (50)	100	50/50	349 (50)	102	50/50
22	359 (49)	49/50	361 (50)	101	50/50	358 (50)	100	50/50	364 (50)	101	50/50
26	372 (49)	49/50	372 (50)	100	50/50	371 (50)	100	50/50	373 (50)	100	50/50
30	383 (49)	49/50	384 (50)	100	50/50	383 (50)	100	50/50	385 (50)	101	50/50
34	389 (49)	49/50	392 (50)	101	50/50	393 (50)	101	50/50	392 (50)	101	50/50
38	403 (49)	49/50	400 (50)	99	50/50	400 (50)	99	50/50	401 (50)	100	50/50
42	409 (49)	49/50	405 (50)	99	50/50	407 (50)	100	50/50	406 (50)	99	50/50
46	416 (49)	49/50	411 (50)	99	50/50	415 (50)	100	50/50	415 (48)	100	48/50
50	421 (49)	49/50	419 (49)	100	49/50	420 (49)	100	49/50	420 (48)	100	48/50
54	420 (49)	49/50	423 (49)	101	49/50	425 (49)	101	49/50	423 (48)	101	48/50
58	426 (49)	49/50	424 (49)	100	49/50	431 (46)	101	46/50	427 (48)	100	48/50
62	431 (49)	49/50	425 (49)	99	49/50	436 (46)	101	46/50	430 (48)	100	48/50
66	433 (49)	49/50	429 (49)	99	49/50	439 (46)	101	46/50	433 (47)	100	47/50
70	436 (49)	49/50	426 (48)	98	48/50	435 (46)	100	46/50	429 (46)	98	46/50
74	436 (49)	49/50	426 (48)	98	48/50	435 (45)	100	45/50	428 (46)	98	46/50
78	434 (49)	49/50	429 (48)	99	48/50	438 (44)	101	44/50	433 (46)	100	46/50
82	434 (47)	47/50	428 (48)	99	48/50	438 (43)	101	43/50	431 (46)	99	46/50
86	427 (47)	47/50	423 (47)	99	47/50	435 (42)	102	42/50	425 (45)	100	45/50
90	426 (44)	44/50	420 (47)	99	47/50	433 (41)	102	41/50	422 (44)	99	44/50
94	425 (43)	43/50	419 (47)	99	47/50	427 (41)	100	41/50	417 (43)	98	43/50
98	422 (41)	41/50	415 (44)	98	44/50	421 (39)	100	39/50	411 (42)	97	42/50
102	407 (36)	36/50	397 (43)	98	43/50	418 (39)	103	39/50	405 (38)	100	38/50
104	401 (36)	36/50	394 (42)	98	42/50	410 (38)	102	38/50	399 (37)	100	37/50

< >:No.of effective animals,():No.of measured animals Av.Wt.: g

TABLE E2

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control		0.02mg/m3		0.2mg/m3		2mg/m3				
	Av.Wt. (g)	No.of Surviv. <50>	Av.Wt. (g)	% of cont. <50>	No.of Surviv.	Av.Wt. (g)	% of cont. <50>	No.of Surviv.	Av.Wt. (g)	% of cont. <50>	No.of Surviv.
0	96 (50)	50/50	96 (50)	100	50/50	96 (50)	100	50/50	96 (50)	100	50/50
1	110 (50)	50/50	109 (50)	99	50/50	109 (50)	99	50/50	107 (50)	97	50/50
2	124 (50)	50/50	124 (50)	100	50/50	123 (50)	99	50/50	121 (50)	98	50/50
3	134 (50)	50/50	133 (50)	99	50/50	133 (50)	99	50/50	132 (50)	99	50/50
4	141 (50)	50/50	142 (50)	101	50/50	141 (50)	100	50/50	140 (50)	99	50/50
5	149 (50)	50/50	149 (50)	100	50/50	148 (50)	99	50/50	147 (50)	99	50/50
6	154 (50)	50/50	155 (50)	101	50/50	155 (50)	101	50/50	154 (50)	100	50/50
7	159 (50)	50/50	158 (50)	99	50/50	158 (50)	99	50/50	158 (50)	99	50/50
8	161 (50)	50/50	162 (50)	101	50/50	162 (50)	101	50/50	162 (50)	101	50/50
9	166 (50)	50/50	167 (50)	101	50/50	166 (50)	100	50/50	167 (50)	101	50/50
10	170 (50)	50/50	171 (50)	101	50/50	171 (50)	101	50/50	173 (50)	102	50/50
11	175 (50)	50/50	176 (50)	101	50/50	175 (50)	100	50/50	177 (50)	101	50/50
12	177 (50)	50/50	179 (50)	101	50/50	178 (50)	101	50/50	179 (50)	101	50/50
13	178 (50)	50/50	181 (50)	102	50/50	181 (50)	102	50/50	182 (50)	102	50/50
14	181 (50)	50/50	183 (50)	101	50/50	185 (50)	102	50/50	185 (50)	102	50/50
18	190 (50)	50/50	192 (50)	101	50/50	191 (50)	101	50/50	192 (50)	101	50/50
22	194 (50)	50/50	199 (50)	103	50/50	197 (50)	102	50/50	198 (50)	102	50/50
26	199 (50)	50/50	202 (50)	102	50/50	202 (50)	102	50/50	201 (50)	101	50/50
30	204 (50)	50/50	207 (50)	101	50/50	208 (50)	102	50/50	208 (50)	102	50/50
34	206 (50)	50/50	211 (49)	102	49/50	212 (50)	103	50/50	212 (50)	103	50/50
38	213 (50)	50/50	217 (49)	102	49/50	216 (50)	101	50/50	216 (50)	101	50/50
42	217 (50)	50/50	220 (49)	101	49/50	219 (50)	101	50/50	221 (49)	102	49/50
46	221 (50)	50/50	224 (49)	101	49/50	224 (50)	101	50/50	224 (49)	101	49/50
50	225 (50)	50/50	225 (49)	100	49/50	227 (50)	101	50/50	227 (49)	101	49/50
54	226 (50)	50/50	229 (48)	101	48/50	231 (49)	102	49/50	232 (49)	103	49/50
58	230 (50)	50/50	232 (48)	101	48/50	234 (49)	102	49/50	235 (49)	102	49/50
62	237 (50)	50/50	237 (47)	100	47/50	241 (49)	102	49/50	243 (48)	103	48/50
66	242 (50)	50/50	242 (47)	100	47/50	244 (49)	101	49/50	245 (48)	101	48/50
70	249 (50)	50/50	249 (47)	100	47/50	251 (49)	101	49/50	253 (47)	102	47/50
74	251 (50)	50/50	251 (47)	100	47/50	255 (48)	102	48/50	256 (47)	102	47/50
78	256 (49)	49/50	257 (47)	100	47/50	262 (46)	102	46/50	259 (47)	101	47/50
82	263 (47)	47/50	262 (47)	100	47/50	265 (46)	101	46/50	260 (45)	99	45/50
86	266 (47)	47/50	264 (47)	99	47/50	265 (46)	100	46/50	262 (44)	98	44/50
90	269 (47)	47/50	270 (45)	100	45/50	266 (45)	99	45/50	262 (44)	97	44/50
94	278 (44)	44/50	269 (43)	97	43/50	274 (43)	99	43/50	265 (41)	95	41/50
98	276 (44)	44/50	268 (42)	97	42/50	275 (42)	100	42/50	264 (40)	96	40/50
102	278 (43)	43/50	265 (38)	95	38/50	277 (40)	100	40/50	264 (36)	95	36/50
104	278 (42)	42/50	265 (34)	95	34/50	277 (39)	100	39/50	261 (36)	94	36/50

< >:No.of effective animals,():No.of measured animals Av.Wt.: g

TABLE E3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		1		2		3		4		5		6	
	0													
Control	120 ± 5		147 ± 7		178 ± 8		202 ± 9		222 ± 10		239 ± 11		252 ± 11	
0.02mg/m3	120 ± 5		148 ± 8		178 ± 8		202 ± 9		223 ± 9		239 ± 10		253 ± 11	
0.2mg/m3	120 ± 5		148 ± 6		178 ± 9		202 ± 10		223 ± 11		239 ± 12		254 ± 13	
2mg/m3	120 ± 5		146 ± 7		176 ± 10		200 ± 10		222 ± 10		239 ± 11		254 ± 12	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		7		8		9		10		11		12		13	
Control	264 ±	12	275 ±	13	285 ±	13	295 ±	14	303 ±	14	310 ±	15	316 ±	16		
0.02mg/m3	262 ±	12	275 ±	13	286 ±	14	296 ±	14	303 ±	15	311 ±	16	318 ±	17		
0.2mg/m3	264 ±	14	276 ±	15	286 ±	16	295 ±	16	303 ±	16	311 ±	16	317 ±	18		
2mg/m3	266 ±	12	279 ±	13	290 ±	14	299 ±	15	307 ±	16	314 ±	16	322 ±	17		

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week											
	14	18	22	26	30	34	38					
Control	322 ± 17	343 ± 18	359 ± 20	372 ± 21	383 ± 23	389 ± 23	403 ± 24					
0.02mg/m3	324 ± 17	344 ± 19	361 ± 20	372 ± 20	384 ± 22	392 ± 25	400 ± 25					
0.2mg/m3	323 ± 18	343 ± 19	358 ± 20	371 ± 21	383 ± 23	393 ± 24	400 ± 25					
2mg/m3	329 ± 17	349 ± 17	364 ± 19	373 ± 19	385 ± 21	392 ± 23	401 ± 24					

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		46		50		54		58		62		66	
	42													
Control	409 ±	25	416 ±	25	421 ±	25	420 ±	25	426 ±	26	431 ±	25	433 ±	26
0.02mg/m3	405 ±	26	411 ±	28	419 ±	25	423 ±	26	424 ±	25	425 ±	26	429 ±	27
0.2mg/m3	407 ±	26	415 ±	27	420 ±	28	425 ±	28	431 ±	23	436 ±	24	439 ±	26
2mg/m3	406 ±	26	415 ±	21	420 ±	21	423 ±	21	427 ±	21	430 ±	20	433 ±	21

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		74		78		82		86		90		94	
	70													
Control	436 ± 26		436 ± 26		434 ± 27		434 ± 30		427 ± 31		426 ± 32		425 ± 39	
0.02mg/m3	426 ± 24		426 ± 24		429 ± 23		428 ± 25		423 ± 28		420 ± 38		419 ± 59*	
0.2mg/m3	435 ± 23		435 ± 26		438 ± 28		438 ± 27		435 ± 23		433 ± 25		427 ± 33	
2mg/m3	429 ± 21		428 ± 21		433 ± 21		431 ± 23		425 ± 25		422 ± 29		417 ± 32	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week					
	98	102	104			
Control	422 ± 65	407 ± 41	401 ± 45			
0.02mg/m3	415 ± 71	397 ± 30	394 ± 37			
0.2mg/m3	421 ± 39	418 ± 51	410 ± 39			
2mg/m3	411 ± 32	405 ± 37	399 ± 38			

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HAN260) BAIS 5

TABLE E4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		1		2		3		4		5		6	
	0													
Control	96 ±	4	110 ±	5	124 ±	6	134 ±	7	141 ±	7	149 ±	7	154 ±	8
0.02mg/m3	96 ±	4	109 ±	5	124 ±	5	133 ±	5	142 ±	6	149 ±	6	155 ±	7
0.2mg/m3	96 ±	4	109 ±	5	123 ±	6	133 ±	6	141 ±	7	148 ±	7	155 ±	8
2mg/m3	96 ±	4	107 ±	4**	121 ±	5	132 ±	5	140 ±	5	147 ±	5	154 ±	6

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		7		8		9		10		11		12		13	
Control	159 ±	9	161 ±	9	166 ±	10	170 ±	10	175 ±	11	177 ±	11	178 ±	10		
0.02mg/m3	158 ±	7	162 ±	8	167 ±	8	171 ±	9	176 ±	9	179 ±	10	181 ±	10		
0.2mg/m3	158 ±	9	162 ±	9	166 ±	10	171 ±	10	175 ±	11	178 ±	11	181 ±	11		
2mg/m3	158 ±	7	162 ±	6	167 ±	8	173 ±	7	177 ±	8	179 ±	7	182 ±	8		

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		18		22		26		30		34		38	
	14													
Control	181 ± 11		190 ± 12		194 ± 13		199 ± 13		204 ± 14		206 ± 14		213 ± 15	
0.02mg/m3	183 ± 10		192 ± 10		199 ± 11		202 ± 11		207 ± 12		211 ± 11		217 ± 12	
0.2mg/m3	185 ± 12		191 ± 11		197 ± 11		202 ± 11		208 ± 12		212 ± 12*		216 ± 13	
2mg/m3	185 ± 8		192 ± 8		198 ± 8		201 ± 8		208 ± 9		212 ± 10*		216 ± 10	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		46		50		54		58		62		66	
Control	217 ±	16	221 ±	16	225 ±	17	226 ±	17	230 ±	18	237 ±	19	242 ±	21
0.02mg/m3	220 ±	13	224 ±	14	225 ±	15	229 ±	16	232 ±	18	237 ±	19	242 ±	18
0.2mg/m3	219 ±	13	224 ±	14	227 ±	14	231 ±	15	234 ±	17	241 ±	19	244 ±	19
2mg/m3	221 ±	10	224 ±	11	227 ±	11	232 ±	12	235 ±	14	243 ±	14	245 ±	14

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		74		78		82		86		90		94	
	70													
Control	249 ±	24	251 ±	23	256 ±	25	263 ±	23	266 ±	24	269 ±	26	278 ±	25
0.02mg/m3	249 ±	19	251 ±	19	257 ±	21	262 ±	27	264 ±	35	270 ±	49	269 ±	27
0.2mg/m3	251 ±	21	255 ±	21	262 ±	21	265 ±	21	265 ±	21	266 ±	26	274 ±	22
2mg/m3	253 ±	15	256 ±	14	259 ±	15	260 ±	15	262 ±	14	262 ±	18	265 ±	16

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week		102		104	
	98					
Control	276 ± 25		278 ± 27		278 ± 31	
0.02mg/m3	268 ± 33		265 ± 28*		265 ± 26	
0.2mg/m3	275 ± 21		277 ± 22		277 ± 23	
2mg/m3	264 ± 20		264 ± 22*		261 ± 26*	

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HAN260) BAIS 5

TABLE F1

FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.02mg/m3		0.2mg/m3		2mg/m3				
	Av.FC.	No.of Surviv. <50>	Av.FC.	% of cont. <50>	No.of Surviv.	Av.FC.	% of cont. <50>	No.of Surviv.	Av.FC.	% of cont. <50>	No.of Surviv.
1-7	14.6 (50)	50/50	15.0 (50)	103	50/50	15.2 (50)	104	50/50	15.0 (50)	103	50/50
2-7	16.2 (50)	50/50	16.0 (50)	99	50/50	16.5 (50)	102	50/50	16.3 (50)	101	50/50
3-7	16.4 (50)	50/50	16.4 (50)	100	50/50	16.7 (50)	102	50/50	16.6 (50)	101	50/50
4-7	16.7 (50)	50/50	17.0 (50)	102	50/50	17.2 (50)	103	50/50	17.3 (50)	104	50/50
5-7	16.7 (50)	50/50	16.6 (50)	99	50/50	17.0 (50)	102	50/50	17.2 (50)	103	50/50
6-7	15.9 (50)	50/50	16.2 (50)	102	50/50	16.6 (50)	104	50/50	16.6 (50)	104	50/50
7-7	16.1 (50)	50/50	16.1 (50)	100	50/50	16.5 (50)	102	50/50	16.4 (50)	102	50/50
8-7	15.9 (50)	50/50	15.7 (50)	99	50/50	16.2 (50)	102	50/50	16.6 (50)	104	50/50
9-7	15.8 (50)	50/50	16.1 (50)	102	50/50	16.1 (50)	102	50/50	16.9 (50)	107	50/50
10-7	16.5 (50)	50/50	16.2 (50)	98	50/50	16.4 (50)	99	50/50	17.0 (50)	103	50/50
11-7	16.1 (50)	50/50	16.2 (50)	101	50/50	16.6 (50)	103	50/50	16.9 (50)	105	50/50
12-7	16.1 (50)	50/50	16.2 (50)	101	50/50	16.3 (50)	101	50/50	16.6 (50)	103	50/50
13-7	16.1 (50)	50/50	16.2 (50)	101	50/50	16.4 (50)	102	50/50	17.0 (50)	106	50/50
14-7	16.0 (50)	50/50	16.2 (50)	101	50/50	16.3 (50)	102	50/50	16.8 (50)	105	50/50
18-7	16.2 (49)	49/50	16.2 (50)	100	50/50	16.4 (50)	101	50/50	16.8 (50)	104	50/50
22-7	16.4 (49)	49/50	16.7 (50)	102	50/50	16.4 (50)	100	50/50	16.8 (50)	102	50/50
26-7	16.5 (49)	49/50	16.6 (50)	101	50/50	16.7 (50)	101	50/50	16.7 (50)	101	50/50
30-7	16.8 (49)	49/50	16.9 (50)	101	50/50	17.0 (50)	101	50/50	17.4 (50)	104	50/50
34-7	16.5 (49)	49/50	17.2 (50)	104	50/50	17.1 (50)	104	50/50	17.4 (50)	105	50/50
38-7	16.9 (49)	49/50	16.9 (50)	100	50/50	17.0 (50)	101	50/50	17.3 (50)	102	50/50
42-7	16.8 (49)	49/50	16.8 (50)	100	50/50	17.1 (50)	102	50/50	17.2 (50)	102	50/50
46-7	16.8 (49)	49/50	17.3 (50)	103	50/50	17.3 (50)	103	50/50	17.6 (48)	105	48/50
50-7	16.8 (49)	49/50	17.3 (49)	103	49/50	17.3 (49)	103	49/50	17.6 (48)	105	48/50
54-7	16.1 (49)	49/50	17.1 (49)	106	49/50	17.3 (49)	107	49/50	17.4 (48)	108	48/50
58-7	16.5 (49)	49/50	16.6 (49)	101	49/50	16.9 (46)	102	46/50	17.2 (48)	104	48/50
62-7	17.0 (49)	49/50	17.0 (49)	100	49/50	17.4 (46)	102	46/50	17.4 (48)	102	48/50
66-7	16.5 (49)	49/50	17.0 (49)	103	49/50	17.2 (46)	104	46/50	17.3 (47)	105	47/50
70-7	17.1 (49)	49/50	16.6 (48)	97	48/50	16.7 (46)	98	46/50	16.6 (46)	97	46/50
74-7	17.1 (49)	49/50	17.3 (48)	101	48/50	17.8 (45)	104	45/50	17.6 (46)	103	46/50
78-7	17.0 (49)	49/50	17.3 (48)	102	48/50	17.5 (44)	103	44/50	17.5 (46)	103	46/50
82-7	17.1 (47)	47/50	17.3 (48)	101	48/50	17.3 (43)	101	43/50	17.5 (46)	102	46/50
86-7	16.7 (47)	47/50	16.9 (47)	101	47/50	16.9 (42)	101	42/50	16.7 (45)	100	45/50
90-7	17.2 (44)	44/50	17.2 (47)	100	47/50	16.9 (41)	98	41/50	16.9 (44)	98	44/50
94-7	16.8 (43)	43/50	17.0 (46)	101	47/50	16.9 (41)	101	41/50	16.9 (43)	101	43/50
98-7	16.4 (41)	41/50	17.1 (43)	104	44/50	17.0 (39)	104	39/50	16.7 (42)	102	42/50
102-7	16.7 (36)	36/50	17.4 (43)	104	43/50	17.0 (39)	102	39/50	16.9 (38)	101	38/50
104-7	16.7 (36)	36/50	17.6 (42)	105	42/50	17.4 (38)	104	38/50	17.0 (37)	102	37/50

< >:No.of effective animals,():No.of measured animals Av.FC.: g

TABLE F2

**FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS : FEMALE**

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.02mg/m3		0.2mg/m3		2mg/m3				
	Av.FC.	No.of Surviv. <50>	Av.FC.	% of cont. <50>	No.of Surviv.	Av.FC.	% of cont. <50>	No.of Surviv.	Av.FC.	% of cont. <50>	No.of Surviv.
1-7	11.2 (50)	50/50	11.2 (50)	100	50/50	11.5 (50)	103	50/50	11.3 (50)	101	50/50
2-7	11.7 (50)	50/50	11.3 (50)	97	50/50	11.7 (50)	100	50/50	11.2 (50)	96	50/50
3-7	11.1 (50)	50/50	10.9 (50)	98	50/50	11.0 (50)	99	50/50	11.0 (50)	99	50/50
4-7	11.2 (50)	50/50	11.2 (50)	100	50/50	11.3 (50)	101	50/50	11.3 (50)	101	50/50
5-7	11.1 (50)	50/50	11.1 (50)	100	50/50	11.5 (50)	104	50/50	11.3 (50)	102	50/50
6-7	10.7 (50)	50/50	10.8 (50)	101	50/50	11.1 (50)	104	50/50	11.0 (50)	103	50/50
7-7	10.7 (50)	50/50	10.5 (50)	98	50/50	10.7 (50)	100	50/50	10.8 (50)	101	50/50
8-7	10.5 (50)	50/50	10.5 (50)	100	50/50	10.7 (50)	102	50/50	10.8 (50)	103	50/50
9-7	10.6 (50)	50/50	10.5 (50)	99	50/50	10.7 (50)	101	50/50	11.2 (50)	106	50/50
10-7	11.1 (50)	50/50	11.0 (50)	99	50/50	11.2 (50)	101	50/50	11.3 (50)	102	50/50
11-7	11.1 (50)	50/50	11.0 (50)	99	50/50	11.1 (50)	100	50/50	11.5 (50)	104	50/50
12-7	11.0 (50)	50/50	11.0 (50)	100	50/50	11.1 (50)	101	50/50	11.2 (49)	102	50/50
13-7	10.5 (50)	50/50	10.7 (49)	102	50/50	11.1 (50)	106	50/50	11.3 (50)	108	50/50
14-7	10.7 (50)	50/50	10.8 (50)	101	50/50	11.2 (50)	105	50/50	11.1 (50)	104	50/50
18-7	10.8 (50)	50/50	10.8 (50)	100	50/50	10.8 (50)	100	50/50	11.0 (50)	102	50/50
22-7	10.8 (50)	50/50	11.2 (50)	104	50/50	11.3 (50)	105	50/50	11.3 (50)	105	50/50
26-7	10.7 (50)	50/50	11.1 (50)	104	50/50	11.4 (50)	107	50/50	11.3 (50)	106	50/50
30-7	10.9 (50)	50/50	11.3 (50)	104	50/50	11.3 (50)	104	50/50	11.6 (50)	106	50/50
34-7	11.0 (50)	50/50	11.1 (49)	101	49/50	11.5 (50)	105	50/50	11.5 (50)	105	50/50
38-7	11.0 (50)	50/50	11.4 (49)	104	49/50	10.9 (50)	99	50/50	11.2 (50)	102	50/50
42-7	11.2 (50)	50/50	11.3 (48)	101	49/50	11.4 (50)	102	50/50	11.3 (49)	101	49/50
46-7	11.3 (50)	50/50	11.5 (49)	102	49/50	11.7 (50)	104	50/50	11.9 (49)	105	49/50
50-7	11.3 (50)	50/50	11.3 (49)	100	49/50	11.5 (50)	102	50/50	11.8 (49)	104	49/50
54-7	10.9 (50)	50/50	11.5 (48)	106	48/50	11.4 (49)	105	49/50	12.0 (49)	110	49/50
58-7	11.1 (50)	50/50	10.9 (48)	98	48/50	11.2 (49)	101	49/50	11.4 (49)	103	49/50
62-7	11.7 (50)	50/50	11.6 (47)	99	47/50	11.9 (49)	102	49/50	11.9 (48)	102	48/50
66-7	11.5 (50)	50/50	11.2 (47)	97	47/50	11.2 (49)	97	49/50	11.1 (48)	97	48/50
70-7	11.9 (50)	50/50	12.1 (47)	102	47/50	12.3 (49)	103	49/50	12.6 (47)	106	47/50
74-7	11.7 (50)	50/50	12.2 (47)	104	47/50	12.5 (48)	107	48/50	12.6 (47)	108	47/50
78-7	12.2 (49)	49/50	12.4 (47)	102	47/50	12.6 (46)	103	46/50	12.5 (47)	102	47/50
82-7	12.3 (47)	47/50	12.4 (47)	101	47/50	12.4 (46)	101	46/50	12.4 (45)	101	45/50
86-7	12.1 (47)	47/50	12.2 (47)	101	47/50	12.2 (46)	101	46/50	12.3 (44)	102	44/50
90-7	12.2 (47)	47/50	12.6 (45)	103	45/50	12.4 (45)	102	45/50	12.1 (44)	99	44/50
94-7	12.8 (44)	44/50	12.8 (43)	100	43/50	12.9 (43)	101	43/50	12.3 (41)	96	41/50
98-7	12.2 (44)	44/50	12.4 (42)	102	42/50	12.6 (42)	103	42/50	12.3 (40)	101	40/50
102-7	12.7 (43)	43/50	12.3 (38)	97	38/50	12.9 (40)	102	40/50	12.3 (36)	97	36/50
104-7	12.6 (42)	42/50	12.7 (34)	101	34/50	12.8 (39)	102	39/50	12.3 (36)	98	36/50

< >:No.of effective animals,():No.of measured animals Av.FC.: g

TABLE F3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)	
Control	14.6± 0.8	16.2± 1.3	16.4± 1.2	16.7± 1.1	16.7± 1.1	15.9± 1.0	16.1± 1.0	
0.02mg/m3	15.0± 1.0*	16.0± 1.2	16.4± 1.1	17.0± 1.1	16.6± 1.2	16.2± 1.0	16.1± 0.9	
0.2mg/m3	15.2± 0.8**	16.5± 1.2	16.7± 1.3	17.2± 1.2	17.0± 1.3	16.6± 1.1**	16.5± 1.2	
2mg/m3	15.0± 0.8	16.3± 1.2	16.6± 1.2	17.3± 1.0	17.2± 1.0	16.6± 1.0**	16.4± 0.9	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)	
Control	15.9 ± 1.1	15.8 ± 1.2	16.5 ± 1.0	16.1 ± 1.0	16.1 ± 1.0	16.1 ± 1.0	16.0 ± 1.1	
0.02mg/m3	15.7 ± 1.1	16.1 ± 1.0	16.2 ± 0.9	16.2 ± 1.0	16.2 ± 1.1	16.2 ± 1.1	16.2 ± 1.0	
0.2mg/m3	16.2 ± 1.1	16.1 ± 1.1	16.4 ± 1.1	16.6 ± 1.1*	16.3 ± 1.2	16.4 ± 1.2	16.3 ± 1.2	
2mg/m3	16.6 ± 1.1**	16.9 ± 1.2**	17.0 ± 1.2	16.9 ± 1.2**	16.6 ± 1.0	17.0 ± 1.0**	16.8 ± 1.0**	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 18-7(7)	week-day(effective) 22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	16.2± 1.0	16.4± 1.1	16.5± 1.0	16.8± 1.2	16.5± 1.2	16.9± 1.0	16.8± 1.0
0.02mg/m3	16.2± 1.1	16.7± 1.0	16.6± 1.0	16.9± 1.1	17.2± 1.3*	16.9± 1.1	16.8± 1.1
0.2mg/m3	16.4± 1.2	16.4± 1.1	16.7± 1.0	17.0± 1.1	17.1± 1.1*	17.0± 1.1	17.1± 1.1
2mg/m3	16.8± 1.0*	16.8± 1.2	16.7± 1.0	17.4± 1.0	17.4± 1.3**	17.3± 1.3	17.2± 1.0

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 46-7(7)	week-day(effective) 50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	16.8± 1.0	16.8± 1.0	16.1± 0.9	16.5± 1.0	17.0± 1.1	16.5± 1.1	17.1± 1.2
0.02mg/m3	17.3± 1.2	17.3± 1.1	17.1± 1.1**	16.6± 0.9	17.0± 1.2	17.0± 1.3	16.6± 1.1
0.2mg/m3	17.3± 1.0*	17.3± 1.0	17.3± 0.9**	16.9± 0.9	17.4± 1.0	17.2± 1.2**	16.7± 1.1
2mg/m3	17.6± 1.0**	17.6± 0.9**	17.4± 1.0**	17.2± 0.9**	17.4± 1.0	17.3± 1.3**	16.6± 0.9

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 74-7(7)	week-day(effective) 78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	17.1± 1.1	17.0± 1.3	17.1± 1.5	16.7± 1.9	17.2± 1.7	16.8± 1.7	16.4± 1.9
0.02mg/m3	17.3± 1.0	17.3± 1.1	17.3± 1.4	16.9± 1.5	17.2± 1.9	17.0± 1.9	17.1± 1.4
0.2mg/m3	17.8± 1.7	17.5± 1.4	17.3± 1.6	16.9± 0.8	16.9± 1.2	16.9± 1.4	17.0± 1.2
2mg/m3	17.6± 1.1	17.5± 1.0	17.5± 1.2	16.7± 1.1	16.9± 2.0	16.9± 1.6	16.7± 2.1

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective)	
	102-7(7)	104-7(7)
Control	16.7 ± 1.7	16.7 ± 2.5
0.02mg/m3	17.4 ± 2.3	17.6 ± 2.3
0.2mg/m3	17.0 ± 1.9	17.4 ± 1.3
2mg/m3	16.9 ± 2.0	17.0 ± 1.9

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HAN260) BAIS 5

TABLE F4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	11.2± 0.7	11.7± 0.6	11.1± 0.8	11.2± 0.8	11.1± 0.8	10.7± 0.8	10.7± 0.9
0.02mg/m3	11.2± 0.7	11.3± 0.8**	10.9± 0.7	11.2± 0.7	11.1± 0.7	10.8± 0.7	10.5± 0.8
0.2mg/m3	11.5± 0.7	11.7± 0.6	11.0± 0.7	11.3± 0.7	11.5± 0.7	11.1± 0.7**	10.7± 0.7
2mg/m3	11.3± 0.5	11.2± 0.6**	11.0± 0.5	11.3± 0.6	11.3± 0.5	11.0± 0.6	10.8± 0.6

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 8-7(7)	week-day(effective) 9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	10.5± 0.9	10.6± 0.8	11.1± 0.9	11.1± 1.0	11.0± 0.9	10.5± 0.7	10.7± 0.8
0.02mg/m3	10.5± 0.6	10.5± 0.8	11.0± 0.8	11.0± 0.7	11.0± 0.9	10.7± 0.8	10.8± 0.8
0.2mg/m3	10.7± 0.8	10.7± 0.9	11.2± 0.9	11.1± 0.8	11.1± 0.9	11.1± 1.0**	11.2± 1.1
2mg/m3	10.8± 0.6	11.2± 0.8**	11.3± 0.7	11.5± 0.7*	11.2± 0.7	11.3± 0.8**	11.1± 0.8*

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 18-7(7)	week-day(effective) 22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	10.8± 0.8	10.8± 0.8	10.7± 0.7	10.9± 0.9	11.0± 0.9	11.0± 1.0	11.2± 1.0
0.02mg/m3	10.8± 0.6	11.2± 0.9*	11.1± 0.8	11.3± 0.8*	11.1± 0.7	11.4± 0.8*	11.3± 0.8
0.2mg/m3	10.8± 0.8	11.3± 0.8*	11.4± 0.8**	11.3± 0.9*	11.5± 0.6**	10.9± 0.9	11.4± 0.9
2mg/m3	11.0± 0.6	11.3± 0.7*	11.3± 0.7**	11.6± 0.8**	11.5± 0.8*	11.2± 0.8	11.3± 1.1

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day(effective)		54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
	46-7(7)	50-7(7)					
Control	11.3± 1.0	11.3± 0.9	10.9± 1.0	11.1± 0.9	11.7± 1.0	11.5± 1.0	11.9± 1.0
0.02mg/m3	11.5± 1.0	11.3± 0.9	11.5± 0.8**	10.9± 0.9	11.6± 1.0	11.2± 0.9	12.1± 1.1
0.2mg/m3	11.7± 1.0	11.5± 0.8	11.4± 0.9*	11.2± 0.9	11.9± 1.2	11.2± 1.0	12.3± 1.1
2mg/m3	11.9± 0.9*	11.8± 1.0*	12.0± 1.0**	11.4± 1.0	11.9± 1.1	11.1± 1.0	12.6± 1.2*

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 74-7(7)	week-day(effective) 78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	11.7± 1.0	12.2± 1.0	12.3± 0.9	12.1± 1.0	12.2± 1.9	12.8± 0.9	12.2± 1.5
0.02mg/m3	12.2± 0.8*	12.4± 1.0	12.4± 1.2	12.2± 1.4	12.6± 2.2	12.8± 1.3	12.4± 1.9
0.2mg/m3	12.5± 1.0**	12.6± 1.1	12.4± 1.2	12.2± 1.1	12.4± 1.9	12.9± 1.3	12.6± 1.7
2mg/m3	12.6± 1.0**	12.5± 1.0	12.4± 1.2	12.3± 0.8	12.1± 2.2	12.3± 1.2	12.3± 1.8

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective)	
	102-7(7)	104-7(7)
Control	12.7 ± 1.4	12.6 ± 2.2
0.02mg/m3	12.3 ± 2.1	12.7 ± 1.6
0.2mg/m3	12.9 ± 1.3	12.8 ± 1.9
2mg/m3	12.3 ± 1.2	12.3 ± 1.9

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HAN260)

TABLE G1

HEMATOLOGY : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 ⁶ / μ l		HEMOGLOBIN g / dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g / dl		PLATELET 10 ³ / μ l	
Control	36	7.51 ±	1.54	12.4 ±	2.9	37.9 ±	7.6	50.4 ±	2.3	16.4 ±	1.3	32.4 ±	1.8	933 ±	263
0.02mg/m3	42	7.33 ±	1.29	11.4 ±	2.2	36.2 ±	5.7	49.6 ±	3.8	15.7 ±	1.7	31.5 ±	1.6*	1030 ±	239
0.2mg/m3	38	7.53 ±	1.30	12.3 ±	2.4	37.8 ±	6.2	50.3 ±	3.3	16.4 ±	1.6	32.5 ±	1.6	916 ±	269
2mg/m3	35	8.68 ±	1.25**	14.3 ±	2.4**	43.3 ±	6.0**	50.0 ±	3.1	16.5 ±	1.6	32.9 ±	1.5	837 ±	203

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

(HCL070)

BAIS 5

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	RETICULOCYTE %	
Control	36	5.3 ±	4.5
0.02mg/m3	42	6.0 ±	3.1*
0.2mg/m3	38	5.0 ±	3.2
2mg/m3	35	3.6 ±	2.4

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

(HCL070)

BAIS 5

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO	EOSINO	BASO	OTHER				
		10 ³ / μ l		NEUTRO		LYMPHO									
Control	36	5.46 ±	8.16	47 ±	11	45 ±	12	4 ±	1	1 ±	1	0 ±	0	2 ±	1
0.02mg/m3	42	4.99 ±	3.34	49 ±	10	43 ±	12	4 ±	1	2 ±	3	0 ±	0	3 ±	2
0.2mg/m3	38	5.67 ±	6.99	49 ±	11	45 ±	12	3 ±	1	1 ±	1	0 ±	0	2 ±	1
2mg/m3	35	5.38 ±	2.07**	52 ±	9	40 ±	9	4 ±	1	2 ±	1**	0 ±	0	2 ±	1

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HCL070)

BAIS 5

TABLE G2

HEMATOLOGY : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	RED BLOOD CELL 10 ⁶ / μ l		HEMOGLOBIN g / dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g / dl		PLATELET 10 ³ / μ l	
Control	41	7.97 ±	0.82	14.7 ±	1.2	43.0 ±	2.9	54.3 ±	3.3	18.5 ±	0.7	34.1 ±	0.9	653 ±	152
0.02mg/m3	34	7.83 ±	1.19	14.1 ±	1.8	42.0 ±	4.5	54.4 ±	5.4	18.2 ±	1.6	33.6 ±	1.1**	694 ±	145
0.2mg/m3	39	7.85 ±	1.03	14.4 ±	1.8	42.1 ±	4.2	54.0 ±	4.9	18.3 ±	1.0	34.0 ±	1.4	626 ±	114
2mg/m3	36	8.18 ±	1.03	14.8 ±	2.1	43.9 ±	5.4	53.7 ±	2.2	18.1 ±	0.9	33.7 ±	1.3	680 ±	182

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

REPORT TYPE : A1

PAGE : 5

Group Name	NO. of Animals	RETICULOCYTE %	
Control	41	3.3 ± 4.2	
0.02mg/m3	34	4.4 ± 4.9	
0.2mg/m3	39	3.6 ± 3.7	
2mg/m3	36	3.7 ± 3.5	

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

(HCL070)

BAIS 5

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO	EOSINO	BASO	OTHER				
		10 ³ / μ l		NEUTRO		LYMPHO									
Control	41	2.05 ±	1.08	43 ±	11	49 ±	11	4 ±	1	2 ±	1	0 ±	0	2 ±	1
0.02mg/m3	34	3.75 ±	7.06*	40 ±	13	52 ±	12	3 ±	1	2 ±	1	0 ±	1	4 ±	7
0.2mg/m3	39	11.25 ±	42.30**	41 ±	16	47 ±	17	3 ±	1**	1 ±	1	0 ±	0	7 ±	21
2mg/m3	36	3.71 ±	3.97**	48 ±	15	44 ±	15	4 ±	1	2 ±	1	1 ±	1	2 ±	1

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

TABLE H1

BIOCHEMISTRY : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g / dl		ALBUMIN g / dl		A/G RATIO		T-BILIRUBIN mg / dl		GLUCOSE mg / dl		T-CHOLESTEROL mg / dl		TRIGLYCERIDE mg / dl	
Control	36	6.2 ±	0.4	2.6 ±	0.2	0.7 ±	0.1	0.08 ±	0.04	195 ±	29	164 ±	61	89 ±	69
0.02mg/m3	42	6.3 ±	0.4	2.6 ±	0.3	0.7 ±	0.1	0.06 ±	0.06**	198 ±	34	173 ±	76	116 ±	111
0.2mg/m3	38	6.2 ±	0.4	2.7 ±	0.2	0.8 ±	0.1	0.15 ±	0.53	205 ±	38	169 ±	47	101 ±	78
2mg/m3	35	6.3 ±	0.2	2.6 ±	0.1	0.7 ±	0.1	0.07 ±	0.03	206 ±	30	176 ±	60	104 ±	62

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	PHOSPHOLIPID mg / dl		AST U / L		ALT U / L		LDH U / L		ALP U / L		G-GTP U / L		CK U / L	
Control	36	242 ±	92	110 ±	48	43 ±	16	152 ±	80	330 ±	122	7.6 ±	5.3	125 ±	48
0.02mg/m3	42	264 ±	121	96 ±	65	38 ±	28*	143 ±	107	340 ±	116	6.4 ±	4.6	138 ±	43
0.2mg/m3	38	249 ±	64	135 ±	118	49 ±	33	164 ±	68	374 ±	193	8.0 ±	5.4	151 ±	46
2mg/m3	35	252 ±	78	100 ±	51	41 ±	21	161 ±	82	309 ±	72	6.8 ±	3.3	140 ±	43

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	UREA NITROGEN mg / dl		CREATININE mg / dl		SODIUM mEq / l		POTASSIUM mEq / l		CHLORIDE mEq / l		CALCIUM mg / dl		INORGANIC PHOSPHORUS mg / dl	
Control	36	20.1 ±	3.5	0.44 ±	0.08	143 ±	2	3.6 ±	0.3	108 ±	2	10.2 ±	0.4	4.0 ±	0.6
0.02mg/m3	42	21.5 ±	4.2	0.45 ±	0.08	143 ±	2	3.4 ±	0.3*	107 ±	2	10.3 ±	0.5	4.1 ±	0.7
0.2mg/m3	38	21.1 ±	3.4	0.45 ±	0.08	142 ±	2	3.4 ±	0.3**	106 ±	2**	10.4 ±	0.3*	4.1 ±	0.7
2mg/m3	35	21.8 ±	2.9	0.48 ±	0.07	142 ±	1	3.4 ±	0.2*	106 ±	2**	10.3 ±	0.2	4.0 ±	0.5

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

(HCL074)

BAIS 5

TABLE H2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g / dl		ALBUMIN g / dl		A/G RATIO		T-BILIRUBIN mg / dl		GLUCOSE mg / dl		T-CHOLESTEROL mg / dl		TRIGLYCERIDE mg / dl	
Control	41	6.7±	0.4	3.4±	0.3	1.1±	0.1	0.06±	0.05	180±	23	136±	24	61±	30
0.02mg/m3	34	6.6±	0.3	3.1±	0.3**	0.9±	0.1**	0.05±	0.03	182±	19	133±	50	63±	73
0.2mg/m3	39	6.7±	0.4	3.3±	0.3	1.0±	0.1**	0.10±	0.19	177±	34	148±	52	96±	98
2mg/m3	36	6.6±	0.4	3.2±	0.3*	1.0±	0.1**	0.06±	0.05	173±	27	138±	43	82±	79

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	PHOSPHOLIPID mg / dl		AST U / L		ALT U / L		LDH U / L		ALP U / L		G-GTP U / L		CK U / L	
Control	41	247 ±	45	130 ±	84	57 ±	23	166 ±	101	196 ±	55	2.1 ±	0.8	124 ±	111
0.02mg/m3	34	238 ±	80	133 ±	104	54 ±	30	159 ±	90	239 ±	103	2.4 ±	1.4	126 ±	40
0.2mg/m3	39	267 ±	83	216 ±	295	64 ±	44	202 ±	109	258 ±	195	3.5 ±	4.5	139 ±	57**
2mg/m3	36	251 ±	77	164 ±	129	65 ±	34	173 ±	85	220 ±	88	2.4 ±	1.0	128 ±	33*

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

REPORT TYPE : A1

Group Name	NO. of Animals	UREA NITROGEN mg / dl		CREATININE mg / dl		SODIUM mEq / l		POTASSIUM mEq / l		CHLORIDE mEq / l		CALCIUM mg / dl		INORGANIC PHOSPHORUS mg / dl	
Control	41	18.0 ±	2.3	0.34 ±	0.03	141 ±	2	3.3 ±	0.3	105 ±	3	10.4 ±	0.4	3.7 ±	0.9
0.02mg/m3	34	18.7 ±	2.7	0.36 ±	0.04	142 ±	2	3.1 ±	0.3*	106 ±	2	10.3 ±	0.4	4.4 ±	0.9*
0.2mg/m3	39	18.1 ±	2.5	0.35 ±	0.05	142 ±	2	3.2 ±	0.5	105 ±	3	10.5 ±	0.5	4.2 ±	1.2
2mg/m3	36	19.0 ±	3.2	0.34 ±	0.05	142 ±	2	3.1 ±	0.3*	105 ±	3	10.4 ±	0.5	4.2 ±	1.1

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

TABLE I1

URINALYSIS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

URINALYSIS

REPORT TYPE : A1

Group Name	NO. of Animals	pH							CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Bilirubin				CHI		
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		+	2+
Control	36	0	1	2	5	4	20	4		0	0	0	2	27	7		36	0	0	0	0	0		22	14	0	0	0	0		36	0	0	0
0.02mg/m3	36	0	0	2	4	12	10	8		0	0	0	8	28	0	**	36	0	0	0	0	0		35	0	1	0	0	0	**	36	0	0	0
0.2mg/m3	35	0	1	0	2	8	14	10		0	0	1	3	28	3		35	0	0	0	0	0		29	5	1	0	0	0	*	34	0	0	1
2mg/m3	34	0	1	0	6	14	6	7	**	0	0	0	5	25	4		34	0	0	0	0	0		30	4	0	0	0	0	**	34	0	0	0

Significant difference ; * : P 0.05 ** : P 0.01

Test of CHI SQUARE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : MALE

URINALYSIS

REPORT TYPE : A1

Group Name	NO. of Animals	Occult blood					CHI	Urobilinogen					CHI
		-	±	+	2+	3+		±	+	2+	3+	4+	
Control	36	35	0	1	0	0		36	0	0	0	0	
0.02mg/m3	36	36	0	0	0	0		36	0	0	0	0	
0.2mg/m3	35	33	0	0	0	2		35	0	0	0	0	
2mg/m3	34	34	0	0	0	0		34	0	0	0	0	

Significant difference ; * : P 0.05 ** : P 0.01

Test of CHI SQUARE

TABLE 12

URINALYSIS : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

URINALYSIS

REPORT TYPE : A1

Group Name	NO. of Animals	pH							CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Bilirubin				CHI		
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		+	2+
Control	43	0	0	3	3	1	19	17		0	5	9	9	14	6		43	0	0	0	0	0		17	21	4	1	0	0		43	0	0	0
0.02mg/m3	30	0	0	1	0	3	10	16		0	1	5	10	14	0		30	0	0	0	0	0		22	7	0	1	0	0	*	30	0	0	0
0.2mg/m3	37	0	0	0	5	1	11	20		0	1	4	5	20	7		37	0	0	0	0	0		12	20	4	1	0	0		37	0	0	0
2mg/m3	33	0	0	0	2	5	16	10		0	1	5	7	15	5		33	0	0	0	0	0		13	19	1	0	0	0		33	0	0	0

Significant difference ; * : P 0.05 ** : P 0.01

Test of CHI SQUARE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcRlj[F344/DuCrj]
 MEASURE. TIME : 1
 SEX : FEMALE

URINALYSIS

REPORT TYPE : A1

Group Name	NO. of Animals	Occult blood					CHI	Urobilinogen					CHI
		-	±	+	2+	3+		±	+	2+	3+	4+	
Control	43	41	0	0	1	1		43	0	0	0	0	
0.02mg/m3	30	30	0	0	0	0		30	0	0	0	0	
0.2mg/m3	37	35	1	0	0	1		37	0	0	0	0	
2mg/m3	33	31	1	1	0	0		33	0	0	0	0	

Significant difference ; * : P 0.05 ** : P 0.01

Test of CHI SQUARE

TABLE J1

GROSS FINDINGS : MALE

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control	0.02mg/m3	0.2mg/m3	2mg/m3
			50 (%)	50 (%)	50 (%)	50 (%)
skin/app	nodule		3 (6)	3 (6)	4 (8)	4 (8)
	erosion		0 (0)	0 (0)	0 (0)	1 (2)
	scab		1 (2)	0 (0)	0 (0)	0 (0)
subcutis	edema		0 (0)	0 (0)	1 (2)	0 (0)
	jaundice		1 (2)	0 (0)	0 (0)	0 (0)
	mass		7 (14)	9 (18)	7 (14)	5 (10)
lung	red		0 (0)	0 (0)	2 (4)	1 (2)
	white zone		0 (0)	1 (2)	6 (12)	46 (92)
	red zone		1 (2)	1 (2)	2 (4)	1 (2)
	black zone		0 (0)	0 (0)	0 (0)	14 (28)
	edema		0 (0)	0 (0)	1 (2)	0 (0)
	nodule		3 (6)	4 (8)	9 (18)	11 (22)
	voluminous		1 (2)	1 (2)	2 (4)	4 (8)
lymph node	enlarged		2 (4)	1 (2)	2 (4)	1 (2)
	black		0 (0)	0 (0)	0 (0)	10 (20)
spleen	enlarged		4 (8)	4 (8)	5 (10)	4 (8)
	nodule		2 (4)	1 (2)	1 (2)	1 (2)
	deformed		0 (0)	0 (0)	1 (2)	0 (0)
heart	enlarged		0 (0)	0 (0)	1 (2)	0 (0)
oral cavity	nodule		1 (2)	0 (0)	2 (4)	0 (0)
	food		0 (0)	1 (2)	2 (4)	2 (4)
tongue	nodule		1 (2)	0 (0)	0 (0)	0 (0)

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control		0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)	50	(%)
salivary gl	nodule		0	(0)	1	(2)	0	(0)	0	(0)
stomach	forestomach:ulcer		0	(0)	1	(2)	1	(2)	0	(0)
	glandular stomach:ulcer		0	(0)	1	(2)	0	(0)	1	(2)
	glandular stomach:red zone		1	(2)	0	(0)	0	(0)	0	(0)
	glandular stomach:thick		0	(0)	0	(0)	2	(4)	0	(0)
small intes	nodule		1	(2)	0	(0)	0	(0)	0	(0)
cecum	gas		0	(0)	0	(0)	1	(2)	0	(0)
	thick		0	(0)	0	(0)	1	(2)	0	(0)
large intes	nodule		1	(2)	0	(0)	0	(0)	1	(2)
liver	enlarged		3	(6)	2	(4)	3	(6)	0	(0)
	white zone		1	(2)	0	(0)	0	(0)	0	(0)
	red zone		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		1	(2)	0	(0)	1	(2)	0	(0)
	cyst		0	(0)	0	(0)	0	(0)	1	(2)
	herniation		7	(14)	6	(12)	5	(10)	6	(12)
kidney	enlarged		0	(0)	0	(0)	2	(4)	0	(0)
	yellow zone		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		1	(2)	0	(0)	2	(4)	0	(0)
	deformed		1	(2)	1	(2)	0	(0)	1	(2)
	granular		2	(4)	5	(10)	2	(4)	2	(4)
urin bladd	nodule		0	(0)	0	(0)	1	(2)	0	(0)
	urine:marked retention		1	(2)	0	(0)	0	(0)	2	(4)

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control		0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)	50	(%)
urin bladd	urine:red		0	(0)	0	(0)	1	(2)	1	(2)
pituitary	enlarged		7	(14)	6	(12)	2	(4)	5	(10)
	red zone		6	(12)	7	(14)	4	(8)	4	(8)
	brown zone		0	(0)	1	(2)	0	(0)	0	(0)
	black zone		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	0	(0)	2	(4)	1	(2)
	cyst		0	(0)	0	(0)	0	(0)	1	(2)
thyroid	enlarged		4	(8)	3	(6)	3	(6)	3	(6)
	nodule		0	(0)	1	(2)	0	(0)	0	(0)
adrenal	enlarged		2	(4)	2	(4)	3	(6)	2	(4)
testis	nodule		27	(54)	37	(74)	32	(64)	34	(68)
brain	enlarged		0	(0)	1	(2)	0	(0)	0	(0)
	red zone		1	(2)	1	(2)	1	(2)	0	(0)
	nodule		0	(0)	0	(0)	0	(0)	1	(2)
spinal cord	red zone		0	(0)	0	(0)	1	(2)	0	(0)
	brown zone		0	(0)	0	(0)	0	(0)	1	(2)
eye	white		5	(10)	1	(2)	2	(4)	1	(2)
Zymbal gl	nodule		1	(2)	0	(0)	1	(2)	0	(0)
muscle	red zone		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	1	(2)	1	(2)	1	(2)
bone	nodule		1	(2)	0	(0)	0	(0)	0	(0)
pleura	black zone		0	(0)	0	(0)	1	(2)	0	(0)

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control					
			50	(%)	50	(%)		
			0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)
pleura	nodule		1	(2)	0	(0)	1	(2)
peritoneum	nodule		0	(0)	3	(6)	1	(2)
retroperit	mass		2	(4)	0	(0)	0	(0)
abdominal c	hemorrhage		0	(0)	0	(0)	0	(0)
	ascites		2	(4)	2	(4)	1	(2)
thoracic ca	hemorrhage		0	(0)	0	(0)	0	(0)
	pleural fluid		2	(4)	2	(4)	2	(4)
other	ear:nodule		0	(0)	1	(2)	0	(0)
	hindlimb:nodule		1	(2)	0	(0)	0	(0)
	nose:nodule		0	(0)	1	(2)	2	(4)
whole body	anemic		0	(0)	0	(0)	1	(2)

TABLE J2

GROSS FINDINGS : FEMALE

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control		0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)	50	(%)
skin/app	nodule		2	(4)	0	(0)	1	(2)	1	(2)
subcutis	jaundice		0	(0)	1	(2)	1	(2)	0	(0)
	mass		5	(10)	9	(18)	7	(14)	6	(12)
nasal cavit	white zone		0	(0)	0	(0)	0	(0)	1	(2)
lung	red		0	(0)	0	(0)	1	(2)	0	(0)
	white zone		2	(4)	1	(2)	3	(6)	48	(96)
	red zone		1	(2)	1	(2)	2	(4)	1	(2)
	black zone		0	(0)	0	(0)	0	(0)	10	(20)
	nodule		1	(2)	0	(0)	5	(10)	7	(14)
	adhesion		1	(2)	1	(2)	0	(0)	0	(0)
	voluminous		0	(0)	1	(2)	1	(2)	2	(4)
lymph node	enlarged		1	(2)	1	(2)	0	(0)	0	(0)
	black		0	(0)	0	(0)	0	(0)	9	(18)
thymus	atrophic		0	(0)	0	(0)	1	(2)	0	(0)
spleen	enlarged		5	(10)	7	(14)	9	(18)	6	(12)
	nodule		1	(2)	0	(0)	1	(2)	1	(2)
	deformed		0	(0)	1	(2)	0	(0)	0	(0)
	adhesion		1	(2)	0	(0)	0	(0)	0	(0)
oral cavity	nodule		0	(0)	1	(2)	0	(0)	0	(0)
	food		2	(4)	3	(6)	2	(4)	3	(6)
tongue	nodule		1	(2)	1	(2)	0	(0)	0	(0)
salivary gl	nodule		1	(2)	0	(0)	2	(4)	0	(0)

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control		0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)	50	(%)
stomach	forestomach:ulcer		0	(0)	2	(4)	1	(2)	0	(0)
	forestomach:thick		0	(0)	0	(0)	1	(2)	0	(0)
	glandular stomach:ulcer		0	(0)	1	(2)	1	(2)	0	(0)
	glandular stomach:erosion		0	(0)	0	(0)	1	(2)	0	(0)
	glandular stomach:thick		0	(0)	1	(2)	0	(0)	0	(0)
small intes	nodule		0	(0)	0	(0)	0	(0)	1	(2)
liver	enlarged		0	(0)	0	(0)	0	(0)	2	(4)
	white zone		0	(0)	2	(4)	2	(4)	4	(8)
	nodule		1	(2)	1	(2)	0	(0)	0	(0)
	rough		1	(2)	4	(8)	5	(10)	1	(2)
	nodular		0	(0)	1	(2)	1	(2)	0	(0)
	herniation		11	(22)	7	(14)	8	(16)	11	(22)
pancreas	nodule		0	(0)	0	(0)	1	(2)	0	(0)
kidney	enlarged		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	0	(0)	0	(0)	1	(2)
	cyst		0	(0)	1	(2)	0	(0)	0	(0)
	granular		0	(0)	1	(2)	0	(0)	0	(0)
urin bladd	nodule		0	(0)	0	(0)	2	(4)	0	(0)
	urine:marked retention		1	(2)	0	(0)	0	(0)	1	(2)
pituitary	enlarged		6	(12)	6	(12)	9	(18)	3	(6)
	red zone		13	(26)	13	(26)	21	(42)	16	(32)
	nodule		1	(2)	0	(0)	2	(4)	4	(8)

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control		0.02mg/m3		0.2mg/m3		2mg/m3	
			50	(%)	50	(%)	50	(%)	50	(%)
pituitary	cyst		0	(0)	0	(0)	1	(2)	0	(0)
thyroid	enlarged		1	(2)	5	(10)	0	(0)	4	(8)
	nodule		0	(0)	1	(2)	0	(0)	0	(0)
adrenal	enlarged		0	(0)	1	(2)	0	(0)	1	(2)
ovary	enlarged		3	(6)	0	(0)	1	(2)	0	(0)
	cyst		1	(2)	1	(2)	2	(4)	1	(2)
uterus	nodule		3	(6)	3	(6)	4	(8)	4	(8)
	dilated lumen		0	(0)	0	(0)	1	(2)	1	(2)
prep/cli gl	nodule		0	(0)	0	(0)	2	(4)	0	(0)
brain	red zone		1	(2)	1	(2)	0	(0)	2	(4)
	hemorrhage		0	(0)	0	(0)	1	(2)	0	(0)
spinal cord	red zone		0	(0)	0	(0)	0	(0)	1	(2)
eye	turbid		0	(0)	0	(0)	0	(0)	1	(2)
	white		2	(4)	3	(6)	3	(6)	1	(2)
	red		0	(0)	1	(2)	0	(0)	0	(0)
	edema		0	(0)	0	(0)	0	(0)	1	(2)
Zymbal gl	nodule		0	(0)	0	(0)	1	(2)	0	(0)
cartilage	nodule		0	(0)	0	(0)	1	(2)	0	(0)
pleura	nodule		0	(0)	0	(0)	0	(0)	2	(4)
mediastinum	mass		0	(0)	1	(2)	0	(0)	0	(0)
	adhesion		0	(0)	1	(2)	0	(0)	0	(0)
peritoneum	nodule		1	(2)	0	(0)	2	(4)	1	(2)

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control	0.02mg/m3	0.2mg/m3	2mg/m3
			50 (%)	50 (%)	50 (%)	50 (%)
peritoneum	adhesion		1 (2)	0 (0)	0 (0)	0 (0)
retroperit	mass		0 (0)	1 (2)	0 (0)	1 (2)
abdominal c	hemorrhage		0 (0)	1 (2)	1 (2)	0 (0)
	ascites		1 (2)	0 (0)	1 (2)	1 (2)
thoracic ca	pleural fluid		0 (0)	2 (4)	0 (0)	1 (2)
other	ear:nodule		0 (0)	0 (0)	0 (0)	1 (2)
	forelimb:nodule		0 (0)	0 (0)	0 (0)	1 (2)
whole body	anemic		0 (0)	1 (2)	1 (2)	0 (0)

TABLE K1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
Control	36	377 ± 43	0.188 ±	0.655	3.242 ±	1.632	1.169 ±	0.097	1.311 ±	0.101	2.692 ±	0.252
0.02mg/m3	42	369 ± 39	0.069 ±	0.020	3.506 ±	1.628	1.202 ±	0.087	1.336 ±	0.115	2.753 ±	0.233
0.2mg/m3	38	385 ± 38	0.108 ±	0.162	3.585 ±	1.449	1.209 ±	0.094	1.505 ±	0.129**	2.741 ±	0.207
2mg/m3	37	376 ± 37	0.070 ±	0.027	3.785 ±	1.957	1.180 ±	0.088	2.373 ±	0.312**	2.783 ±	0.300

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	36	1.066 ±	0.382	10.823 ±	1.778	2.038 ±	0.056
0.02mg/m3	42	2.697 ±	10.234	11.206 ±	1.401	2.045 ±	0.051
0.2mg/m3	38	1.058 ±	0.287	11.102 ±	1.220	2.061 ±	0.055
2mg/m3	37	1.127 ±	0.575	11.004 ±	1.301	2.059 ±	0.044

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

(HCL040)

BAIS 5

TABLE K2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
Control	42	260 ± 29	0.065 ±	0.009	0.235 ±	0.675	0.830 ±	0.062	0.903 ±	0.213	1.748 ±	0.139
0.02mg/m3	34	248 ± 25	0.059 ±	0.008**	0.149 ±	0.092	0.827 ±	0.067	0.936 ±	0.102**	1.739 ±	0.131
0.2mg/m3	39	258 ± 23	0.066 ±	0.009	0.177 ±	0.324	0.849 ±	0.063	1.142 ±	0.266**	1.816 ±	0.189
2mg/m3	36	243 ± 26*	0.071 ±	0.015*	0.124 ±	0.031	0.843 ±	0.060	1.866 ±	0.179**	1.825 ±	0.156

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	42	0.656 ±	0.653	6.542 ±	0.993	1.850 ±	0.056
0.02mg/m3	34	0.750 ±	0.577	6.587 ±	0.994	1.854 ±	0.049
0.2mg/m3	39	0.839 ±	0.972	6.987 ±	1.239	1.862 ±	0.054
2mg/m3	36	0.646 ±	0.228	6.520 ±	0.797	1.859 ±	0.045

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

TABLE L1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	36	377 ± 43	0.054 ± 0.195	0.854 ± 0.421	0.314 ± 0.044	0.355 ± 0.060	0.725 ± 0.123
0.02mg/m3	42	369 ± 39	0.019 ± 0.006	0.951 ± 0.437	0.328 ± 0.035	0.369 ± 0.045	0.754 ± 0.101
0.2mg/m3	38	385 ± 38	0.034 ± 0.076	0.927 ± 0.349	0.318 ± 0.042	0.399 ± 0.060**	0.721 ± 0.107
2mg/m3	37	376 ± 37	0.019 ± 0.008	1.011 ± 0.544	0.317 ± 0.038	0.652 ± 0.198**	0.748 ± 0.120

Significant difference ; * : P 0.05 ** : P 0.01

Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	36	0.283 ± 0.091	2.874 ± 0.330	0.549 ± 0.077
0.02mg/m3	42	0.740 ± 2.820	3.051 ± 0.382	0.560 ± 0.053
0.2mg/m3	38	0.277 ± 0.075	2.910 ± 0.383	0.543 ± 0.074
2mg/m3	37	0.314 ± 0.244	2.941 ± 0.339	0.554 ± 0.073

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HCL042)

BAIS 5

TABLE L2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	42	260 ± 29	0.025 ± 0.004	0.094 ± 0.281	0.322 ± 0.034	0.353 ± 0.103	0.677 ± 0.081
0.02mg/m3	34	248 ± 25	0.024 ± 0.005	0.060 ± 0.034	0.336 ± 0.032	0.376 ± 0.049**	0.707 ± 0.082
0.2mg/m3	39	258 ± 23	0.026 ± 0.005	0.067 ± 0.110	0.331 ± 0.033	0.445 ± 0.136**	0.708 ± 0.094
2mg/m3	36	243 ± 26*	0.030 ± 0.008**	0.051 ± 0.012	0.349 ± 0.036**	0.786 ± 0.158**	0.759 ± 0.121**

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

STUDY NO. : 0800
ANIMAL : RAT F344/DuCrIj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	42	0.258 ± 0.282	2.522 ± 0.366	0.719 ± 0.079
0.02mg/m3	34	0.299 ± 0.210**	2.665 ± 0.371	0.755 ± 0.077
0.2mg/m3	39	0.341 ± 0.460	2.725 ± 0.563	0.727 ± 0.073
2mg/m3	36	0.269 ± 0.102**	2.692 ± 0.309**	0.773 ± 0.097*

Significant difference ; * : P 0.05 ** : P 0.01 Test of Dunnett

(HCL042)

BAIS 5

TABLE M1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Integumentary system/appandage}						
skin/app	squamous cell papilloma		<50> 0 (0%)	<50> 2 (4%)	<50> 3 (6%)	<50> 2 (4%)
	keratoacanthoma		2 (4%)	2 (4%)	0 (0%)	3 (6%)
	neural crest neoplasm:benign		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	trichoepithelioma:malignant		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	basal cell carcinoma		0 (0%)	0 (0%)	2 (4%)	0 (0%)
subcutis	fibroma		<50> 4 (8%)	<50> 8 (16%)	<50> 5 (10%)	<50> 3 (6%)
	lipoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
	fibrosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	liposarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Respiratory system}						
nasal cavit	chondroma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)
lung	bronchiolar-alveolar adenoma		<50> 1 (2%)	<50> 1 (2%)	<50> 7 (14%)	<50> 5 (10%)
	adenosquamous carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Crlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Respiratory system}						
Lung	bronchiolar-alveolar carcinoma		<50> 1 (2%)	<50> 1 (2%)	<50> 8 (16%)	<50> 10 (20%)
{Hematopoietic system}						
bone marrow	histiocytic sarcoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
Lymph node	malignant lymphoma		<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)
spleen	malignant lymphoma		<50> 0 (0%)	<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)
	mononuclear cell leukemia		4 (8%)	4 (8%)	3 (6%)	4 (8%)
	hemangiosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Digestive system}						
oral cavity	squamous cell carcinoma		<50> 0 (0%)	<50> 0 (0%)	<50> 2 (4%)	<50> 0 (0%)
tongue	squamous cell papilloma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)
salivary gl	adenocarcinoma		<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)
stomach	squamous cell papilloma		<50> 0 (0%)	<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)
small intes	leiomyosarcoma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Digestive system}						
large intes	fibrosarcoma		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
liver	hepatocellular adenoma		<50> 0 (0%)	<50> 3 (6%)	<50> 0 (0%)	<50> 0 (0%)
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hepatocellular carcinoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
pancreas	islet cell adenoma		<50> 5 (10%)	<50> 3 (6%)	<50> 4 (8%)	<50> 4 (8%)
	islet cell adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Urinary system}						
kidney	nephroblastoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
urin bladd	transitional cell papilloma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
{Endocrine system}						
pituitary	adenoma		<50> 6 (12%)	<50> 6 (12%)	<50> 5 (10%)	<50> 6 (12%)
	thyroid	C-cell adenoma	<50> 12 (24%)	<50> 9 (18%)	<50> 7 (14%)	<50> 10 (20%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Endocrine system}						
thyroid	follicular adenoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
	C-cell carcinoma		0 (0%)	1 (2%)	1 (2%)	1 (2%)
adrenal	pheochromocytoma		<50> 3 (6%)	<50> 5 (10%)	<50> 4 (8%)	<50> 3 (6%)
	pheochromocytoma:malignant		1 (2%)	5 (10%)	4 (8%)	0 (0%)
{Reproductive system}						
testis	interstitial cell tumor		<50> 36 (72%)	<50> 42 (84%)	<50> 41 (82%)	<50> 40 (80%)
mammary gl	fibroadenoma		<50> 1 (2%)	<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)
	adenocarcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
prep/cli gl	adenoma		<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)	<50> 1 (2%)
{Nervous system}						
brain	glioma		<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)	<50> 1 (2%)
spinal cord	glioma		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
{Special sense organs/appendage}						
Zymbal gl	squamous cell carcinoma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Crlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Special sense organs/appendage}						
Zymbal gl	sarcoma:NOS		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
{Musculoskeletal system}						
muscle	schwannoma:malignant		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)
bone	osteoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
	osteosarcoma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)
{Body cavities}						
pleura	histiocytic sarcoma		<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)
	carcinoma:NOS		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
mediastinum	histiocytic sarcoma		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)
peritoneum	mesothelioma		<50> 0 (0%)	<50> 3 (6%)	<50> 1 (2%)	<50> 1 (2%)
retroperit	neuroendocrine cell tumor:benign		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
	neuroendocrine cell tumor:malignant		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
	sarcoma:NOS		<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE M2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Crlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	fibroma		0 (0%)	2 (4%)	0 (0%)	0 (0%)
	lipoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	epidermal cyst		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	fibrosarcoma		0 (0%)	0 (0%)	1 (2%)	1 (2%)
{Respiratory system}						
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		3 (6%)	1 (2%)	4 (8%)	3 (6%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	adenocarcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	adenosquamous carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	bronchiolar-alveolar carcinoma		0 (0%)	1 (2%)	0 (0%)	5 (10%)
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	malignant lymphoma		0 (0%)	2 (4%)	0 (0%)	0 (0%)
spleen			<50>	<50>	<50>	<50>
	mononuclear cell leukemia		6 (12%)	7 (14%)	9 (18%)	6 (12%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Digestive system}						
oral cavity	squamous cell papilloma		<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)
salivary gl	adenocarcinoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
	sarcoma:NOS		0 (0%)	0 (0%)	1 (2%)	0 (0%)
small intes	histiocytic sarcoma		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
liver	hepatocellular adenoma		<50> 1 (2%)	<50> 0 (0%)	<50> 4 (8%)	<50> 0 (0%)
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hepatocellular carcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
pancreas	islet cell adenoma		<50> 1 (2%)	<50> 1 (2%)	<50> 1 (2%)	<50> 1 (2%)
{Urinary system}						
kidney	nephroblastoma		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
urin bladd	transitional cell carcinoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 1 (2%)
{Endocrine system}						
pituitary	adenoma		<50> 9 (18%)	<50> 9 (18%)	<50> 11 (22%)	<50> 10 (20%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Endocrine system}						
pituitary	adenocarcinoma		<50> 0 (0%)	<50> 2 (4%)	<50> 0 (0%)	<50> 0 (0%)
thyroid	C-cell adenoma		<50> 2 (4%)	<50> 7 (14%)	<50> 1 (2%)	<50> 6 (12%)
	follicular adenoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
	C-cell carcinoma		1 (2%)	2 (4%)	1 (2%)	2 (4%)
	follicular adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
adrenal	pheochromocytoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 2 (4%)
	ganglioneuroma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	pheochromocytoma:malignant		0 (0%)	0 (0%)	1 (2%)	1 (2%)
	ganglioneuroma:malignant		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Reproductive system}						
ovary	granulosa-theca cell tumor		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
uterus	endometrial stromal polyp		<50> 9 (18%)	<50> 8 (16%)	<50> 5 (10%)	<50> 5 (10%)
	adenocarcinoma		2 (4%)	0 (0%)	1 (2%)	3 (6%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Crlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Reproductive system}						
uterus	leiomyosarcoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
	endometrial stromal sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
mammary gl	adenoma		<50> 1 (2%)	<50> 1 (2%)	<50> 1 (2%)	<50> 0 (0%)
	fibroadenoma		3 (6%)	5 (10%)	7 (14%)	6 (12%)
	adenocarcinoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
prep/cli gl	adenoma		<50> 2 (4%)	<50> 0 (0%)	<50> 3 (6%)	<50> 0 (0%)
{Special sense organs/appendage}						
Zymbal gl	adenoma		<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)
{Musculoskeletal system}						
muscle	fibroma		<50> 0 (0%)	<50> 0 (0%)	<50> 0 (0%)	<50> 1 (2%)
{Body cavities}						
retroperit	fibroma		<50> 0 (0%)	<50> 1 (2%)	<50> 0 (0%)	<50> 0 (0%)

< a > a : Number of animals examined at the site
 b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE N1

NEOPLASTIC LESIONS-INCIDENCE
AND STATISTICAL ANALYSIS : MALE

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : skin/appendage TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50(0.0)	2/50(4.0)	3/50(6.0)	2/50(4.0)
Adjusted rates(b)	0.0	4.76	7.89	4.88
Terminal rates(c)	0/36(0.0)	2/42(4.8)	3/38(7.9)	1/37(2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3429			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7288			
Fisher Exact test(e)		P = 0.2475	P = 0.1212	P = 0.2475
SITE : skin/appendage TUMOR : keratoacanthoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	2/50(4.0)	0/50(0.0)	3/50(6.0)
Adjusted rates(b)	5.56	4.76	0.0	6.82
Terminal rates(c)	2/36(5.6)	2/42(4.8)	0/38(0.0)	2/37(5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1653			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.3224			
Fisher Exact test(e)		P = 0.6913	P = 0.2475	P = 0.5000
SITE : subcutis TUMOR : fibroma				
Tumor rate				
Overall rates(a)	4/50(8.0)	8/50(16.0)	5/50(10.0)	3/50(6.0)
Adjusted rates(b)	9.09	13.04	7.89	8.11
Terminal rates(c)	3/36(8.3)	4/42(9.5)	3/38(7.9)	3/37(8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8504			
Prevalence method(d)	P = 0.7511			
Combined analysis(d)	P = 0.8671			
Cochran-Armitage test(e)	P = 0.2677			
Fisher Exact test(e)		P = 0.1783	P = 0.5000	P = 0.5000

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : subcutis TUMOR : fibroma, fibrosarcoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	8/50(16.0)	5/50(10.0)	3/50(6.0)
Adjusted rates(b)	9.09	13.04	7.89	8.11
Terminal rates(c)	3/36(8.3)	4/42(9.5)	3/38(7.9)	3/37(8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8504			
Prevalence method(d)	P = 0.7511			
Combined analysis(d)	P = 0.8671			
Cochran-Armitage test(e)	P = 0.2677			
Fisher Exact test(e)		P = 0.1783	P = 0.5000	P = 0.5000
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	7/50(14.0)	5/50(10.0)
Adjusted rates(b)	2.78	2.38	18.42	12.20
Terminal rates(c)	1/36(2.8)	1/42(2.4)	7/38(18.4)	4/37(10.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1170			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2273			
Fisher Exact test(e)		P = 0.7525	P = 0.0297*	P = 0.1022
SITE : lung TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	8/50(16.0)	10/50(20.0)
Adjusted rates(b)	2.78	2.38	21.05	24.32
Terminal rates(c)	1/36(2.8)	1/42(2.4)	8/38(21.1)	9/37(24.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0019**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0031**			
Fisher Exact test(e)		P = 0.7525	P = 0.0154*	P = 0.0039**

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : lung TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	2/50(4.0)	13/50(26.0)	15/50(30.0)
Adjusted rates(b)	5.56	4.76	34.21	35.14
Terminal rates(c)	2/36(5.6)	2/42(4.8)	13/38(34.2)	13/37(35.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0003**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0006**			
Fisher Exact test(e)		P = 0.6913	P = 0.0019**	P = 0.0005**
SITE : lung TUMOR : bronchiolar-alveolar carcinoma,adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	8/50(16.0)	11/50(22.0)
Adjusted rates(b)	2.78	2.38	21.05	27.03
Terminal rates(c)	1/36(2.8)	1/42(2.4)	8/38(21.1)	10/37(27.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0007**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0010**			
Fisher Exact test(e)		P = 0.7525	P = 0.0154*	P = 0.0019**
SITE : lung TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma,adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	2/50(4.0)	13/50(26.0)	16/50(32.0)
Adjusted rates(b)	5.56	4.76	34.21	37.84
Terminal rates(c)	2/36(5.6)	2/42(4.8)	13/38(34.2)	14/37(37.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0001**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0002**			
Fisher Exact test(e)		P = 0.6913	P = 0.0019**	P = 0.0002**

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : spleen TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	4/50(8.0)	4/50(8.0)	3/50(6.0)	4/50(8.0)
Adjusted rates(b)	5.56	6.98	2.63	5.41
Terminal rates(c)	2/36(5.6)	2/42(4.8)	1/38(2.6)	2/37(5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3764			
Prevalence method(d)	P = 0.4849			
Combined analysis(d)	P = 0.4227			
Cochran-Armitage test(e)	P = 0.9094			
Fisher Exact test(e)		P = 0.6425	P = 0.5000	P = 0.6425
SITE : liver TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	0/50(0.0)	0/50(0.0)
Adjusted rates(b)	0.0	7.14	0.0	0.0
Terminal rates(c)	0/36(0.0)	3/42(7.1)	0/38(0.0)	0/37(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8701			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2651			
Fisher Exact test(e)		P = 0.1212	P = N.C.	P = N.C.
SITE : liver TUMOR : hepatocellular adenoma,hepatocellular carcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	4/50(8.0)	1/50(2.0)	0/50(0.0)
Adjusted rates(b)	0.0	9.52	2.63	0.0
Terminal rates(c)	0/36(0.0)	4/42(9.5)	1/38(2.6)	0/37(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9239			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1775			
Fisher Exact test(e)		P = 0.0587	P = 0.5000	P = N.C.

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : pancreas TUMOR : islet cell adenoma				
Tumor rate				
Overall rates(a)	5/50(10.0)	3/50(6.0)	4/50(8.0)	4/50(8.0)
Adjusted rates(b)	11.36	7.14	9.76	10.81
Terminal rates(c)	4/36(11.1)	3/42(7.1)	3/38(7.9)	4/37(10.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4626			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.9950			
Fisher Exact test(e)		P = 0.3575	P = 0.5000	P = 0.5000
SITE : pancreas TUMOR : islet cell adenoma, islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	5/50(10.0)	4/50(8.0)	4/50(8.0)	4/50(8.0)
Adjusted rates(b)	11.36	9.30	9.76	10.81
Terminal rates(c)	4/36(11.1)	3/42(7.1)	3/38(7.9)	4/37(10.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5267			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8666			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : pituitary gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	6/50(12.0)	6/50(12.0)	5/50(10.0)	6/50(12.0)
Adjusted rates(b)	8.33	11.90	10.53	4.88
Terminal rates(c)	3/36(8.3)	5/42(11.9)	4/38(10.5)	1/37(2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1061			
Prevalence method(d)	P = 0.8228			
Combined analysis(d)	P = 0.4410			
Cochran-Armitage test(e)	P = 0.9252			
Fisher Exact test(e)		P = 0.6202	P = 0.5000	P = 0.6202

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	12/50(24.0)	9/50(18.0)	7/50(14.0)	10/50(20.0)
Adjusted rates(b)	30.00	21.43	16.67	24.32
Terminal rates(c)	10/36(27.8)	9/42(21.4)	5/38(13.2)	9/37(24.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4256			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.9161			
Fisher Exact test(e)		P = 0.3121	P = 0.1540	P = 0.4048
SITE : thyroid TUMOR : C-cell adenoma,C-cell carcinoma				
Tumor rate				
Overall rates(a)	12/50(24.0)	10/50(20.0)	8/50(16.0)	11/50(22.0)
Adjusted rates(b)	30.00	23.81	19.05	25.00
Terminal rates(c)	10/36(27.8)	10/42(23.8)	6/38(15.8)	9/37(24.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3796			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8271			
Fisher Exact test(e)		P = 0.4048	P = 0.2270	P = 0.5000
SITE : adrenal gland TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	5/50(10.0)	4/50(8.0)	3/50(6.0)
Adjusted rates(b)	8.33	11.11	9.76	8.11
Terminal rates(c)	3/36(8.3)	2/42(4.8)	3/38(7.9)	3/37(8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6456			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.6480			
Fisher Exact test(e)		P = 0.3575	P = 0.5000	P = 0.6611

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : adrenal gland TUMOR : pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	1/50(2.0)	5/50(10.0)	4/50(8.0)	0/50(0.0)
Adjusted rates(b)	2.78	11.90	10.53	0.0
Terminal rates(c)	1/36(2.8)	5/42(11.9)	4/38(10.5)	0/37(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9755			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0718			
Fisher Exact test(e)		P = 0.1022	P = 0.1811	P = 0.5000
SITE : adrenal gland TUMOR : pheochromocytoma,pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	4/50(8.0)	10/50(20.0)	8/50(16.0)	3/50(6.0)
Adjusted rates(b)	11.11	22.22	19.51	8.11
Terminal rates(c)	4/36(11.1)	7/42(16.7)	7/38(18.4)	3/37(8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9401			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1211			
Fisher Exact test(e)		P = 0.0739	P = 0.1783	P = 0.5000
SITE : testis TUMOR : interstitial cell tumor				
Tumor rate				
Overall rates(a)	36/50(72.0)	42/50(84.0)	41/50(82.0)	40/50(80.0)
Adjusted rates(b)	83.33	88.64	95.35	97.30
Terminal rates(c)	30/36(83.3)	37/42(88.1)	36/38(94.7)	36/37(97.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3550			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8680			
Fisher Exact test(e)		P = 0.1135	P = 0.1710	P = 0.2415

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : peritoneum				
TUMOR : mesothelioma				
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	1/50(2.0)	1/50(2.0)
Adjusted rates(b)	0.0	7.14	2.63	2.70
Terminal rates(c)	0/36(0.0)	3/42(7.1)	1/38(2.6)	1/37(2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5491			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7807			
Fisher Exact test(e)		P = 0.1212	P = 0.5000	P = 0.5000

(HPT360A)

BAISS

- (a): Number of tumor-bearing animals/number of animals examined at the site.
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c): Observed tumor incidence at terminal kill.
 (d): Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference ; * : P 0.05 ** : P 0.01
 N.C.:Statistical value cannot be calculated and was not significant.

TABLE N2

**NEOPLASTIC LESIONS-INCIDENCE
AND STATISTICAL ANALYSIS : FEMALE**

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	1/50(2.0)	4/50(8.0)	3/50(6.0)
Adjusted rates(b)	7.14	2.94	9.52	8.33
Terminal rates(c)	3/42(7.1)	1/34(2.9)	3/39(7.7)	3/36(8.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3275			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7913			
Fisher Exact test(e)		P = 0.3087	P = 0.5000	P = 0.6611
SITE : lung TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	0/50(0.0)	5/50(10.0)
Adjusted rates(b)	0.0	2.94	0.0	12.50
Terminal rates(c)	0/42(0.0)	1/34(2.9)	0/39(0.0)	4/36(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0007**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0009**			
Fisher Exact test(e)		P = 0.5000	P = N.C.	P = 0.0281*
SITE : lung TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	2/50(4.0)	4/50(8.0)	8/50(16.0)
Adjusted rates(b)	7.14	5.88	9.52	20.00
Terminal rates(c)	3/42(7.1)	2/34(5.9)	3/39(7.7)	7/36(19.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0116*			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0250*			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0999

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma,squamous cell carcinoma,adenocarcinoma,adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	0/50(0.0)	8/50(16.0)
Adjusted rates(b)	0.0	2.94	0.0	20.00
Terminal rates(c)	0/42(0.0)	1/34(2.9)	0/39(0.0)	7/36(19.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = 0.5000	P = N.C.	P = 0.0029**
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma,squamous cell carcinoma,adenocarcinoma,adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	2/50(4.0)	4/50(8.0)	11/50(22.0)
Adjusted rates(b)	7.14	5.88	9.52	27.78
Terminal rates(c)	3/42(7.1)	2/34(5.9)	3/39(7.7)	10/36(27.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0005**			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0010**			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0204*
SITE : spleen				
TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	6/50(12.0)	7/50(14.0)	9/50(18.0)	6/50(12.0)
Adjusted rates(b)	4.76	5.88	7.69	2.78
Terminal rates(c)	2/42(4.8)	2/34(5.9)	3/39(7.7)	1/36(2.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4189			
Prevalence method(d)	P = 0.7434			
Combined analysis(d)	P = 0.5781			
Cochran-Armitage test(e)	P = 0.6972			
Fisher Exact test(e)		P = 0.5000	P = 0.2883	P = 0.6202

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	0/50(0.0)	4/50(8.0)	0/50(0.0)
Adjusted rates(b)	2.38	0.0	8.89	0.0
Terminal rates(c)	1/42(2.4)	0/34(0.0)	3/39(7.7)	0/36(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8484			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2857			
Fisher Exact test(e)		P = 0.5000	P = 0.1811	P = 0.5000
SITE : liver				
TUMOR : hepatocellular adenoma,hepatocellular carcinoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	4/50(8.0)	0/50(0.0)
Adjusted rates(b)	2.38	2.50	8.89	0.0
Terminal rates(c)	1/42(2.4)	0/34(0.0)	3/39(7.7)	0/36(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8959			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2143			
Fisher Exact test(e)		P = 0.7525	P = 0.1811	P = 0.5000
SITE : pituitary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	9/50(18.0)	9/50(18.0)	11/50(22.0)	10/50(20.0)
Adjusted rates(b)	21.43	16.67	23.08	25.00
Terminal rates(c)	9/42(21.4)	5/34(14.7)	9/39(23.1)	9/36(25.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6008			
Prevalence method(d)	P = 0.2536			
Combined analysis(d)	P = 0.3267			
Cochran-Armitage test(e)	P = 0.8756			
Fisher Exact test(e)		P = 0.6024	P = 0.4016	P = 0.5000

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : pituitary gland TUMOR : adenoma,adenocarcinoma				
Tumor rate				
Overall rates(a)	9/50(18.0)	11/50(22.0)	11/50(22.0)	10/50(20.0)
Adjusted rates(b)	21.43	19.44	23.08	25.00
Terminal rates(c)	9/42(21.4)	6/34(17.6)	9/39(23.1)	9/36(25.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6868			
Prevalence method(d)	P = 0.2941			
Combined analysis(d)	P = 0.4094			
Cochran-Armitage test(e)	P = 0.9442			
Fisher Exact test(e)		P = 0.4016	P = 0.4016	P = 0.5000
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	7/50(14.0)	1/50(2.0)	6/50(12.0)
Adjusted rates(b)	4.76	16.67	2.56	15.79
Terminal rates(c)	2/42(4.8)	4/34(11.8)	1/39(2.6)	5/36(13.9)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1191			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2818			
Fisher Exact test(e)		P = 0.0798	P = 0.5000	P = 0.1343
SITE : thyroid TUMOR : C-cell adenoma,C-cell carcinoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	8/50(16.0)	2/50(4.0)	8/50(16.0)
Adjusted rates(b)	7.14	19.44	5.13	21.05
Terminal rates(c)	3/42(7.1)	5/34(14.7)	2/39(5.1)	7/36(19.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0702			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1769			
Fisher Exact test(e)		P = 0.0999	P = 0.5000	P = 0.0999

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : uterus TUMOR : endometrial stromal polyp				
Tumor rate				
Overall rates(a)	9/50(18.0)	8/50(16.0)	5/50(10.0)	5/50(10.0)
Adjusted rates(b)	18.37	17.39	10.42	11.11
Terminal rates(c)	7/42(16.7)	5/34(14.7)	2/39(5.1)	4/36(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P = 0.8910			
Combined analysis(d)	P = 0.7910			
Cochran-Armitage test(e)	P = 0.3449			
Fisher Exact test(e)		P = 0.5000	P = 0.1940	P = 0.1940
SITE : uterus TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	0/50(0.0)	1/50(2.0)	3/50(6.0)
Adjusted rates(b)	0.0	0.0	0.0	8.33
Terminal rates(c)	0/42(0.0)	0/34(0.0)	0/39(0.0)	3/36(8.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8293			
Prevalence method(d)	P = 0.0012**?			
Combined analysis(d)	P = 0.0856			
Cochran-Armitage test(e)	P = 0.1557			
Fisher Exact test(e)		P = 0.2475	P = 0.5000	P = 0.5000
SITE : mammary gland TUMOR : fibroadenoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	5/50(10.0)	7/50(14.0)	6/50(12.0)
Adjusted rates(b)	7.14	9.76	14.58	15.79
Terminal rates(c)	3/42(7.1)	3/34(8.8)	4/39(10.3)	5/36(13.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2020			
Combined analysis(d)	P = 0.2485			
Cochran-Armitage test(e)	P = 0.6115			
Fisher Exact test(e)		P = 0.3575	P = 0.1589	P = 0.2435

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : mammary gland				
TUMOR : adenoma, fibroadenoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	6/50(12.0)	8/50(16.0)	6/50(12.0)
Adjusted rates(b)	8.89	12.20	16.67	15.79
Terminal rates(c)	3/42(7.1)	3/34(8.8)	5/39(12.8)	5/36(13.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.3560			
Combined analysis(d)	P = 0.4085			
Cochran-Armitage test(e)	P = 0.9173			
Fisher Exact test(e)		P = 0.3703	P = 0.1783	P = 0.3703
SITE : mammary gland				
TUMOR : adenoma, fibroadenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	7/50(14.0)	9/50(18.0)	6/50(12.0)
Adjusted rates(b)	8.89	14.63	19.05	15.79
Terminal rates(c)	3/42(7.1)	4/34(11.8)	6/39(15.4)	5/36(13.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.4435			
Combined analysis(d)	P = 0.4952			
Cochran-Armitage test(e)	P = 0.9021			
Fisher Exact test(e)		P = 0.2623	P = 0.1168	P = 0.3703

STUDY No. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
SITE : preputial/clitoral gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	0/50(0.0)	3/50(6.0)	0/50(0.0)
Adjusted rates(b)	4.76	0.0	7.69	0.0
Terminal rates(c)	2/42(4.8)	0/34(0.0)	3/39(7.7)	0/36(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8765			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2397			
Fisher Exact test(e)		P = 0.2475	P = 0.5000	P = 0.2475

(HPT360A)

BAISS

- (a): Number of tumor-bearing animals/number of animals examined at the site.
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c): Observed tumor incidence at terminal kill.
 (d): Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference ; * : P 0.05 ** : P 0.01
 N.C.:Statistical value cannot be calculated and was not significant.

TABLE 01

**HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :
F344/DuCr1Cr1j MALE RATS**

TABLE O1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS
IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j MALE RATS

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Lung	599			
Bronchiolar-alveolar adenoma		35	5.8	2 - 12
Bronchiolar-alveolar carcinoma		6	1.0	0 - 4
Adenosquamous carcinoma		0	0.0	0 - 0
Bronchiolar-alveolar adenoma + Bronchiolar-alveolar carcinoma		41	6.8	2 - 12

12 carcinogenicity inhalation studies examined in Japan Bioassay Research Center were used.
Study No. : 0457, 0535, 0560, 0610, 0667, 0675, 0686, 0704, 0731, 0753, 0774, 0794

TABLE 02

**HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :
F344/DuCr1Cr1j FEMALE RATS**

TABLE 02 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS
IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j FEMALE RATS

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Lung	600			
Bronchiolar-alveolar carcinoma		0	0.0	0 - 0
Squamous cell carcinoma		0	0.0	0 - 0
Adenosquamous carcinoma		0	0.0	0 - 0
Adenocarcinoma, poorly-differentiated		0	0.0	0 - 0
Uterus	600			
Endometrial stromal polyp		87	14.5	6 - 26

12 carcinogenicity inhalation studies examined in Japan Bioassay Research Center were used.
Study No. : 0457, 0535, 0560, 0610, 0667, 0675, 0686, 0704, 0731, 0753, 0774, 0794

TABLE P1

HISTOPATHOLOGICAL FINDINGS :
NON-NEOPLASTIC LESIONS : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Integumentary system/appandage}																	
skin/app	ulcer	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	inflammation	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)
	sebaceous hyperplasia	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Respiratory system}																	
nasal cavit	thrombus	<50>				<50>				<50>				<50>			
		3	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0
		(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	mineralization	20	0	0	0	24	0	0	0	11	0	0	0	5	0	0	0 **
		(40)	(0)	(0)	(0)	(48)	(0)	(0)	(0)	(22)	(0)	(0)	(0)	(10)	(0)	(0)	(0)
	goblet cell hyperplasia	1	0	0	0	2	0	0	0	15	1	0	0 **	7	38	0	0 **
		(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(30)	(2)	(0)	(0)	(14)	(76)	(0)	(0)
	eosinophilic change:olfactory epithelium	26	12	1	0	37	9	1	0	1	2	45	0 **	1	6	41	0 **
		(52)	(24)	(2)	(0)	(74)	(18)	(2)	(0)	(2)	(4)	(90)	(0)	(2)	(12)	(82)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50					
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
{Respiratory system}																			
nasal cavit																			
	eosinophilic change:respiratory epithelium		<50>				<50>				<50>				<50>				
		10 (20)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	48 (96)	0 (0)	0 (0)	0 (0)	0 (0)	46 (92)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammation:foreign body	29 (58)	0 (0)	0 (0)	0 (0)	23 (46)	0 (0)	0 (0)	0 (0)	15 (30)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation:respiratory epithelium	12 (24)	0 (0)	0 (0)	0 (0)	17 (34)	1 (2)	0 (0)	0 (0)	16 (32)	0 (0)	0 (0)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:olfactory epithelium	5 (10)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:gland	45 (90)	0 (0)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	47 (94)	1 (2)	0 (0)	0 (0)	0 (0)	28 (56)	20 (40)	0 (0)	0 (0)	0 (0)
	hyperplasia:transitional epithelium	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	16 (32)	0 (0)	0 (0)	0 (0)	0 (0)	28 (56)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of fiber	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	42 (84)	0 (0)	0 (0)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	0 (0)
nasopharynx																			
	goblet cell hyperplasia		<50>				<50>				<50>				<50>				
		0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	18 (36)	0 (0)	0 (0)	0 (0)	0 (0)	33 (66)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Respiratory system}																	
nasopharynx	inflammation:foreign body	<50>				<50>				<50>				<50>			
		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
larynx	inflammation	<50>				<50>				<50>				<50>			
		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
	lymphocytic infiltration	<50>				<50>				<50>				<50>			
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
inflammation:foreign body	<50>				<50>				<50>				<50>				
	5 (10)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	
deposit of fiber	<50>				<50>				<50>				<50>				
	0 (0)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	26 (52)	0 (0)	0 (0)	0 (0)	40 (80)	0 (0)	0 (0)	0 (0)	
trachea	deposit of fiber	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	30 (60)	0 (0)	0 (0)	0 (0)	49 (98)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)
lung	congestion	<50>				<50>				<50>				<50>			
		1 (2)	2 (4)	0 (0)	0 (0)	1 (2)	3 (6)	1 (2)	0 (0)	1 (2)	1 (2)	2 (4)	0 (0)	0 (0)	5 (10)	2 (4)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Respiratory system}																	
Lung	hemorrhage	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	edema	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	atypical hyperplasia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	7 (14)	3 (6)	0 (0)
	bronchiolar-alveolar cell hyperplasia	1 (2)	1 (2)	0 (0)	0 (0)	4 (8)	2 (4)	0 (0)	0 (0)	10 (20)	3 (6)	0 (0)	0 (0)	0 (0)	21 (42)	1 (2)	0 (0)
	inflammation:foreign body	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	infiltration:alveolar macrophage	2 (4)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	0 (0)	17 (34)	31 (62)	0 (0)
	hyperplasia:pneumocyte	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	0 (0)	39 (78)	2 (4)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Respiratory system}																	
Lung		<50>				<50>				<50>				<50>			
	hyperplasia:terminal bronchiole	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0) **
	thickening:pleura	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	18 (36)	1 (2)	0 (0)	0 (0) **
	granulomatous change	0 (0)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	42 (84)	0 (0)	0 (0)	0 (0) **	7 (14)	43 (86)	0 (0)	0 (0) **
	thickening:alveolar wall,focal	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	42 (84)	1 (2)	0 (0)	0 (0) **	12 (24)	36 (72)	0 (0)	0 (0) **
	deposit of fiber:alveolar wall	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0) **	48 (96)	0 (0)	0 (0)	0 (0) **
	deposit of fiber :bronchus-associated lymphoid tissue	0 (0)	0 (0)	0 (0)	0 (0)	36 (72)	0 (0)	0 (0)	0 (0) **	40 (80)	8 (16)	0 (0)	0 (0) **	32 (64)	18 (36)	0 (0)	0 (0) **
	deposit of fiber:bronchiole	0 (0)	0 (0)	0 (0)	0 (0)	35 (70)	0 (0)	0 (0)	0 (0) **	45 (90)	0 (0)	0 (0)	0 (0) **	48 (96)	0 (0)	0 (0)	0 (0) **
	deposit of fiber:alveolar space	0 (0)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0) **	50 (100)	0 (0)	0 (0)	0 (0) **	3 (6)	47 (94)	0 (0)	0 (0) **

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50																			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)												
{Hematopoietic system}																																	
bone marrow																																	
	granulation		<50>					<50>					<50>					<50>															
		4	0	0	0	1	1	0	0	4	1	0	0	4	1	0	0	(8)	(2)	(2)	(0)	(0)											
		(8)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(8)	(2)	(0)	(0)	(8)	(2)	(0)	(0)	(8)	(2)	(0)	(0)												
	increased hematopoiesis	9	0	0	0	9	0	0	0	6	0	0	0	5	0	0	0	(18)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(10)	(0)	(0)	(0)				
		(18)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(10)	(0)	(0)					
	decreased hematopoiesis	22	4	0	0	10	3	0	0 *	21	3	0	0	25	4	0	0	(44)	(8)	(0)	(0)	(20)	(6)	(0)	(0)	(42)	(6)	(0)	(0)	(50)	(8)	(0)	(0)
		(44)	(8)	(0)	(0)	(20)	(6)	(0)	(0)	(42)	(6)	(0)	(0)	(50)	(8)	(0)	(0)	(44)	(8)	(0)	(0)	(20)	(6)	(0)	(0)	(42)	(6)	(0)	(0)	(50)	(8)	(0)	(0)
	myelofibrosis	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	0	(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	
		(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	
lymph node																																	
	deposit of fiber:mediastinum		<50>					<50>					<50>					<50>															
		0	0	0	0	15	0	0	0 **	30	0	0	0 **	21	26	0	0 **	(0)	(0)	(0)	(0)	(30)	(0)	(0)	(0)	(60)	(0)	(0)	(0)	(42)	(52)	(0)	(0)
		(0)	(0)	(0)	(0)	(30)	(0)	(0)	(0)	(60)	(0)	(0)	(0)	(42)	(52)	(0)	(0)	(0)	(0)	(0)	(0)	(30)	(0)	(0)	(0)	(60)	(0)	(0)	(0)	(42)	(52)	(0)	(0)
	deposit of fiber:others	0	0	0	0	6	0	0	0 *	22	0	0	0 **	47	0	0	0 **	(0)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(44)	(0)	(0)	(0)	(94)	(0)	(0)	(0)
		(0)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(44)	(0)	(0)	(0)	(94)	(0)	(0)	(0)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(44)	(0)	(0)	(0)	(94)	(0)	(0)	(0)	(0)
spleen																																	
	deposit of hemosiderin		<50>					<50>					<50>					<50>															
		20	6	1	0	16	1	0	0	21	7	0	0	23	8	0	0	(40)	(12)	(2)	(0)	(32)	(2)	(0)	(0)	(42)	(14)	(0)	(0)	(46)	(16)	(0)	(0)
		(40)	(12)	(2)	(0)	(32)	(2)	(0)	(0)	(42)	(14)	(0)	(0)	(46)	(16)	(0)	(0)	(40)	(12)	(2)	(0)	(32)	(2)	(0)	(0)	(42)	(14)	(0)	(0)	(46)	(16)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
{Hematopoietic system}																		
spleen		<50>				<50>				<50>				<50>				
	fibrosis:focal	2 (4)	1 (2)	1 (2)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	
	granuloma	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	
	extramedullary hematopoiesis	10 (20)	5 (10)	1 (2)	0 (0)	9 (18)	2 (4)	1 (2)	0 (0)	7 (14)	7 (14)	0 (0)	0 (0)	14 (28)	2 (4)	0 (0)	0 (0)	
	fatty metamorphosis	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
	deposit of fiber	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	27 (54)	0 (0)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)
{Circulatory system}																		
heart		<50>				<50>				<50>				<50>				
	thrombus	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
	mineralization	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50					
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		
{Circulatory system}																			
heart		<50>				<50>				<50>				<50>					
	inflammatory cell nest	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	
	myocardial fibrosis	26 (52)	4 (8)	0 (0)	0 (0)	24 (48)	0 (0)	0 (0)	0 (0)	0 (0)	21 (42)	0 (0)	0 (0)	0 (0)	0 (0)	24 (48)	1 (2)	0 (0)	0 (0)
	endocarditis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
	subendocardial fibrosis	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
artery/aort		<50>				<50>				<50>				<50>					
	mineralization	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
{Digestive system}																			
oral cavity		<50>				<50>				<50>				<50>					
	squamous cell hyperplasia	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
tongue	inflammation:foreign body	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
	arteritis	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
salivary gl	atrophy:focal	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
esophagus	ulcer	<50>				<50>				<50>				<50>			
		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach	inflammatory infiltration	<50>				<50>				<50>				<50>			
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erosion:forestomach	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ulcer:forestomach	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
stomach		<50>				<50>				<50>				<50>			
	hyperplasia:forestomach	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	erosion:glandular stomach	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	ulcer:glandular stomach	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:glandular stomach	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
small intes		<50>				<50>				<50>				<50>			
	inflammatory infiltration	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:epithelium	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
large intes		<50>				<50>				<50>				<50>			
	inflammation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																	
liver																	
		<50>				<50>				<50>				<50>			
herniation		7 (14)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
congestion		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
edema		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
necrosis:central		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
necrosis:focal		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
fatty change		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
fatty change:central		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																	
liver																	
		<50>				<50>				<50>				<50>			
	inflammatory cell nest	8 (16)	1 (2)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	acidophilic cell focus	26 (52)	2 (4)	1 (2)	0 (0)	24 (48)	7 (14)	0 (0)	0 (0)	19 (38)	4 (8)	0 (0)	0 (0)	19 (38)	5 (10)	1 (2)	0 (0)
	basophilic cell focus	13 (26)	0 (0)	0 (0)	0 (0)	14 (28)	2 (4)	0 (0)	0 (0)	7 (14)	1 (2)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)
	mixed cell focus	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	spongiosis hepatitis	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	bile duct hyperplasia	23 (46)	25 (50)	0 (0)	0 (0)	24 (48)	26 (52)	0 (0)	0 (0)	22 (44)	27 (54)	0 (0)	0 (0)	20 (40)	23 (46)	5 (10)	0 (0)
	cholangiofibrosis	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	biliary cyst	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
liver	deposit of fiber	<50>				<50>				<50>				<50>			
		0	0	0	0	3	0	0	0	48	0	0	0 **	50	0	0	0 **
		(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(96)	(0)	(0)	(0)	(100)	(0)	(0)	(0)
pancreas	ectopic tissue	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	
	atrophy:focal	16	5	0	0	8	3	0	0	16	4	0	0	10	5	0	0
(32)	(10)	(0)	(0)	(16)	(6)	(0)	(0)	(32)	(8)	(0)	(0)	(20)	(10)	(0)	(0)		
islet cell hyperplasia	5	0	0	0	5	0	0	0	4	0	0	0	3	0	0	0	
(10)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(6)	(0)	(0)	(0)		
{Urinary system}																	
kidney	cyst	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
hyaline droplet	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)		

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}																	
kidney																	
	fatty metamorphosis	<50>				<50>				<50>				<50>			
		1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
	chronic nephropathy	16 (32)	23 (46)	9 (18)	0 (0)	11 (22)	23 (46)	14 (28)	0 (0)	14 (28)	22 (44)	10 (20)	0 (0)	7 (14)	23 (46)	17 (34)	0 (0)
	tubular necrosis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
	papillary necrosis	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	mineralization:cortico-medullary junction	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	dilatation:tubular lumen	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	urothelial hyperplasia:pelvis	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	atypical tubule hyperplasia	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50							
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}																					
kidney																					
	dilated pelvis		<50>					<50>					<50>					<50>			
		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	regeneration:renal tubule	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)
	deposit of fiber	0	0	0	0	2	0	0	0	49	0	0	0	0	50	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(98)	(0)	(0)	(0)	(0)	(100)	(0)	(0)	(0)	(0)	(0)	(0)
urin blad																					
	obstruction		<50>					<50>					<50>					<50>			
		0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hemorrhage	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	simple hyperplasia:transitional epithelium	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)
{Endocrine system}																					
pituitary																					
	cystic change		<50>					<50>					<50>					<50>			
		16	10	0	0	9	12	0	0	13	10	0	0	7	8	0	0	0	0	0	0
		(32)	(20)	(0)	(0)	(18)	(24)	(0)	(0)	(26)	(20)	(0)	(0)	(14)	(16)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Endocrine system}																	
pituitary	hyperplasia	11 (22)	18 (36)	1 (2)	0 (0)	8 (16)	10 (20)	1 (2)	0 (0)	9 (18)	20 (40)	0 (0)	0 (0)	4 (8)	15 (30)	0 (0)	0 (0)
	Rathke pouch	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
thyroid	ultimobranchial body remanet	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	C-cell hyperplasia	9 (18)	2 (4)	0 (0)	0 (0)	8 (16)	2 (4)	0 (0)	0 (0)	8 (16)	7 (14)	0 (0)	0 (0)	12 (24)	4 (8)	0 (0)	0 (0)
adrenal	extramedullary hematopoiesis	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:medulla	22 (44)	5 (10)	0 (0)	0 (0)	21 (42)	11 (22)	0 (0)	0 (0)	25 (50)	7 (14)	0 (0)	0 (0)	27 (54)	10 (20)	0 (0)	0 (0)
	focal fatty change:cortex	6 (12)	1 (2)	0 (0)	0 (0)	10 (20)	1 (2)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	5 (10)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}																	
testis	arteritis	<50>				<50>				<50>				<50>			
		2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)
	interstitial cell hyperplasia	22 (44)	0 (0)	0 (0)	0 (0)	34 (68)	0 (0)	0 (0)	0 (0)	32 (64)	0 (0)	0 (0)	0 (0)	33 (66)	0 (0)	0 (0)	0 (0)
epididymis	inflammation	<50>				<50>				<50>				<50>			
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
semin ves	inflammation	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
prostate	inflammation	<50>				<50>				<50>				<50>			
		1 (2)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
mammary gl	duct ectasia	<50>				<50>				<50>				<50>			
		9 (18)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Nervous system}																	
brain	hemorrhage	<50>				<50>				<50>				<50>			
		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of fiber:olfactory bulb	0	0	0	0	3	0	0	0	25	0	0	0 **	43	0	0	0 **
		(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(50)	(0)	(0)	(0)	(86)	(0)	(0)	(0)
spinal cord	gliosis	<50>				<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Special sense organs/appendage}																	
eye	cataract	<50>				<50>				<50>				<50>			
		1	4	0	0	2	0	0	0	2	0	0	0	2	0	0	0
		(2)	(8)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	retinal atrophy	1	2	3	0	2	0	1	0	2	0	2	0	0	1	1	0
		(2)	(4)	(6)	(0)	(4)	(0)	(2)	(0)	(4)	(0)	(4)	(0)	(0)	(2)	(2)	(0)
	keratitis	3	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(6)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Special sense organs/appendage}																	
eye	iritis	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Harder gl	inflammatory infiltration	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	granulomatous inflammation	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Musculoskeletal system}																	
muscle	hemorrhage	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	epidermal cyst	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
bone	osteosclerosis	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Body cavities}																	
pleura																	
	inflammation	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	fibrosis:focal	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	simple hyperplasia:mesothelium	3 (6)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)
	papillary hyperplasia:mesothelium	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of fiber	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	17 (34)	0 (0)	0 (0)	0 (0)	32 (64)	0 (0)	0 (0)	0 (0)
mediastinum																	
	inflammatory infiltration	<50>				<50>				<50>				<50>			
		15 (30)	0 (0)	0 (0)	0 (0)	18 (36)	0 (0)	0 (0)	0 (0)	21 (42)	0 (0)	0 (0)	0 (0)	26 (52)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

TABLE P2

HISTOPATHOLOGICAL FINDINGS :
NON-NEOPLASTIC LESIONS : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
{Integumentary system/appandage}																		
subcutis	abscess	<50>				<50>				<50>				<50>				
		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
{Respiratory system}																		
nasal cavit	exudate	<50>				<50>				<50>				<50>				
		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	0 (0) **
	angiectasis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
	thrombus	6 (12)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)
	mineralization	9 (18)	0 (0)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	0 (0)
	exudate:neutrophil leukocyte	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	goblet cell hyperplasia	9 (18)	1 (2)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	35 (70)	3 (6)	0 (0)	0 (0) **	19 (38)	26 (52)	0 (0)	0 (0) **	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50					
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		
{Respiratory system}																			
nasal cavit																			
	eosinophilic change:olfactory epithelium	6 (12)	31 (62)	12 (24)	0 (0)	11 (22)	25 (50)	13 (26)	0 (0)	0 (0)	1 (2)	49 (98)	0 (0)	0 (0)	1 (2)	12 (24)	37 (74)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium	38 (76)	0 (0)	0 (0)	0 (0)	31 (62)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation:foreign body	6 (12)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation:respiratory epithelium	12 (24)	0 (0)	0 (0)	0 (0)	16 (32)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:olfactory epithelium	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:gland	49 (98)	0 (0)	0 (0)	0 (0)	49 (98)	0 (0)	0 (0)	0 (0)	48 (96)	2 (4)	0 (0)	0 (0)	0 (0)	39 (78)	8 (16)	0 (0)	0 (0)	0 (0)
	ulcer:respiratory epithelium	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:transitional epithelium	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50						
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)			
{Respiratory system}																				
nasal cavit	deposit of fiber	<50>				<50>				<50>				<50>						
		0 (0)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	0 (0)	41 (82)	0 (0)	0 (0)	0 (0)	0 (0)	44 (88)	0 (0)	0 (0)	0 (0)	0 (0)
nasopharynx	goblet cell hyperplasia	<50>				<50>				<50>				<50>						
		7 (14)	0 (0)	0 (0)	0 (0)	22 (44)	0 (0)	0 (0)	0 (0)	0 (0)	35 (70)	0 (0)	0 (0)	0 (0)	0 (0)	23 (46)	0 (0)	0 (0)	0 (0)	0 (0)
		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
larynx	ulcer	<50>				<50>				<50>				<50>						
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
larynx	inflammation:foreign body	<50>				<50>				<50>				<50>						
		0 (0)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	0 (0)	28 (56)	0 (0)	0 (0)	0 (0)	0 (0)	43 (86)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50						
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)			
{Respiratory system}																				
trachea	deposit of fiber	<50>				<50>				<50>				<50>						
		0 (0)	0 (0)	0 (0)	0 (0)	29 (58)	0 (0)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)	0 (0)
lung	congestion	<50>				<50>				<50>				<50>						
		0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)
	hemorrhage	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	edema	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	atypical hyperplasia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	12 (24)	2 (4)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia	2 (4)	1 (2)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	7 (14)	1 (2)	0 (0)	0 (0)	0 (0)	11 (22)	1 (2)	0 (0)	0 (0)	0 (0)
	infiltration:alveolar macrophage	2 (4)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	0 (0)	10 (20)	38 (76)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3				
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	
{Respiratory system}																		
Lung	hyperplasia:pneumocyte	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	36 (72)	5 (10)	0 (0)	0 (0)	**
	hyperplasia:terminal bronchiole	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	26 (52)	0 (0)	0 (0)	0 (0)	**
	thickening:pleura	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	20 (40)	0 (0)	0 (0)	0 (0)	**
	granulomatous change	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0)	8 (16)	42 (84)	0 (0)	0 (0)	**
	thickening:alveolar wall,focal	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	44 (88)	0 (0)	0 (0)	0 (0)	38 (76)	11 (22)	0 (0)	0 (0)	**
	deposit of fiber:alveolar wall	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)	0 (0)	**
	deposit of fiber :bronchus-associated lymphoid tissue	0 (0)	0 (0)	0 (0)	0 (0)	44 (88)	0 (0)	0 (0)	0 (0)	43 (86)	5 (10)	0 (0)	0 (0)	21 (42)	29 (58)	0 (0)	0 (0)	**
	deposit of fiber:bronchiole	0 (0)	0 (0)	0 (0)	0 (0)	26 (52)	0 (0)	0 (0)	0 (0)	48 (96)	0 (0)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	**

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																	
Lung	deposit of fiber:alveolar space	<50>				<50>				<50>				<50>			
		0	0	0	0	50	0	0	0 **	50	0	0	0 **	1	49	0	0 **
		(0)	(0)	(0)	(0)	(100)	(0)	(0)	(0)	(100)	(0)	(0)	(0)	(2)	(98)	(0)	(0)
{Hematopoietic system}																	
bone marrow	granulation	<50>				<50>				<50>				<50>			
		16	4	0	0	13	3	0	0	10	3	0	0	12	2	0	0
		(32)	(8)	(0)	(0)	(26)	(6)	(0)	(0)	(20)	(6)	(0)	(0)	(24)	(4)	(0)	(0)
	increased hematopoiesis	8	0	0	0	9	0	0	0	8	0	0	0	8	0	0	0
		(16)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(16)	(0)	(0)	(0)	(16)	(0)	(0)	(0)
	decreased hematopoiesis	17	18	0	0	14	13	0	0	14	20	0	0	16	13	1	0
		(34)	(36)	(0)	(0)	(28)	(26)	(0)	(0)	(28)	(40)	(0)	(0)	(32)	(26)	(2)	(0)
Lymph node	deposit of fiber:mediastinum	<50>				<50>				<50>				<50>			
		0	0	0	0	17	0	0	0 **	29	0	0	0 **	12	32	0	0 **
		(0)	(0)	(0)	(0)	(34)	(0)	(0)	(0)	(58)	(0)	(0)	(0)	(24)	(64)	(0)	(0)
	deposit of fiber:others	0	0	0	0	1	0	0	0	13	0	0	0 **	43	0	0	0 **
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(86)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Hematopoietic system}																	
thymus		<50>				<50>				<50>				<50>			
	ectopic tissue	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
spleen		<50>				<50>				<50>				<50>			
	deposit of hemosiderin	10 (20)	31 (62)	0 (0)	0 (0)	9 (18)	30 (60)	0 (0)	0 (0)	9 (18)	30 (60)	0 (0)	0 (0)	16 (32)	23 (46)	0 (0)	0 (0)
	fibrosis:focal	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	granuloma	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	extramedullary hematopoiesis	19 (38)	3 (6)	1 (2)	0 (0)	24 (48)	8 (16)	0 (0)	0 (0)	23 (46)	4 (8)	0 (0)	0 (0)	21 (42)	3 (6)	3 (6)	0 (0)
	deposit of fiber	0 (0)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	21 (42)	0 (0)	0 (0)	0 (0)	46 (92)	0 (0)	0 (0)	0 (0)
{Circulatory system}																	
heart		<50>				<50>				<50>				<50>			
	inflammatory cell nest	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Circulatory system}																	
heart		<50>				<50>				<50>				<50>			
	myocardial fibrosis	7 (14)	0 (0)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
	subendocardial fibrosis	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																	
oral cavity		<50>				<50>				<50>				<50>			
	inflammation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
tooth		<50>				<50>				<50>				<50>			
	cyst	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
tongue		<50>				<50>				<50>				<50>			
	squamous cell hyperplasia	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	arteritis	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
esophagus	ulcer	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach	erosion:forestomach	<50>				<50>				<50>				<50>			
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ulcer:forestomach	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	3 (6)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
		hyperplasia:forestomach	2 (4)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
	erosion:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
hyperplasia:glandular stomach	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
liver	herniation	<50>				<50>				<50>				<50>			
		10 (20)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
liver																	
	congestion	<50>				<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)
	necrosis:central	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal	0	0	1	0	2	0	0	0	0	0	0	0	1	0	0	0
		(0)	(0)	(2)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	inflammatory infiltration	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory cell nest	16	2	0	0	14	3	1	0	13	5	0	0	17	2	1	0
		(32)	(4)	(0)	(0)	(28)	(6)	(2)	(0)	(26)	(10)	(0)	(0)	(34)	(4)	(2)	(0)
	acidophilic cell focus	1	2	0	0	1	1	0	0	0	2	0	0	0	0	0	0
		(2)	(4)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)
	basophilic cell focus	36	1	0	0	34	0	0	0	29	1	0	0	31	4	0	0
		(72)	(2)	(0)	(0)	(68)	(0)	(0)	(0)	(58)	(2)	(0)	(0)	(62)	(8)	(0)	(0)
	mixed cell focus	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
liver	bile duct hyperplasia	16 (32)	0 (0)	0 (0)	0 (0)	20 (40)	2 (4)	0 (0)	0 (0)	12 (24)	1 (2)	0 (0)	0 (0)	16 (32)	1 (2)	0 (0)	0 (0)
	cholangiofibrosis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	deposit of fiber	0 (0)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	50 (100)	0 (0)	0 (0)
pancreas	atrophy:focal	4 (8)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	islet cell hyperplasia	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
{Urinary system}																	
kidney	cyst	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Urinary system}																	
kidney																	
		<50>				<50>				<50>				<50>			
deposit of hemosiderin		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
chronic nephropathy		31	4	1	0	30	2	2	0	30	5	2	0	22	8	2	0
		(62)	(8)	(2)	(0)	(60)	(4)	(4)	(0)	(60)	(10)	(4)	(0)	(44)	(16)	(4)	(0)
dilatation:tubular lumen		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
regeneration:proximal tubule		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
desquamation:pelvis		1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
dilated pelvis		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
nephrosclerosis		0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
deposit of fiber		0	0	0	0	3	0	0	0	48	0	0	0 **	50	0	0	0 **
		(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(96)	(0)	(0)	(0)	(100)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
{Urinary system}																		
urin bladd	inflammation	<50>				<50>				<50>				<50>				
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
{Endocrine system}																		
pituitary	cystic change	<50>				<50>				<50>				<50>				
		15 (30)	22 (44)	0 (0)	0 (0)	17 (34)	20 (40)	0 (0)	0 (0)	4 (8)	33 (66)	0 (0)	0 (0)	0 (0)	16 (32)	23 (46)	0 (0)	0 (0)
	hyperplasia	14 (28)	7 (14)	0 (0)	0 (0)	14 (28)	9 (18)	1 (2)	0 (0)	14 (28)	13 (26)	1 (2)	0 (0)	0 (0)	7 (14)	9 (18)	0 (0)	0 (0)
	Rathke pouch	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
thyroid	ultimobranchial body remanet	<50>				<50>				<50>				<50>				
		2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	C-cell hyperplasia	5 (10)	2 (4)	0 (0)	0 (0)	5 (10)	4 (8)	0 (0)	0 (0)	8 (16)	3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Endocrine system}																	
thyroid		<50>				<50>				<50>				<50>			
	cystic thyroid follicle	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
adrenal		<50>				<50>				<50>				<50>			
	extramedullary hematopoiesis	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hyperplasia:cortical cell	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:medulla	7 (14)	1 (2)	0 (0)	0 (0)	10 (20)	2 (4)	0 (0)	0 (0)	4 (8)	3 (6)	0 (0)	0 (0)	6 (12)	5 (10)	0 (0)	0 (0)
	focal fatty change:cortex	3 (6)	2 (4)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	3 (6)	5 (10)	0 (0)	0 (0)
{Reproductive system}																	
ovary		<50>				<50>				<50>				<50>			
	cyst	1 (2)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	2 (4)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.02mg/m3 50				0.2mg/m3 50				2mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}																	
uterus	dilatation	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	cystic endometrial hyperplasia	6 (12)	1 (2)	1 (2)	0 (0)	6 (12)	3 (6)	1 (2)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	3 (6)	3 (6)	1 (2)	0 (0)
mammary gl	hyperplasia	<50>				<50>				<50>				<50>			
		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Nervous system}																	
brain	hemorrhage	<50>				<50>				<50>				<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	mineralization	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	deposit of fiber:olfactory bulb	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	21 (42)	0 (0)	0 (0)	0 (0)	41 (82)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrIcrlj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Nervous system}																	
spinal cord	gliosis	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
{Special sense organs/appendage}																	
eye	cataract	<50>				<50>				<50>				<50>			
		1	1	0	0	0	3	0	0	2	1	0	0	0	1	0	0
		(2)	(2)	(0)	(0)	(0)	(6)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(2)	(0)	(0)
	retinal atrophy	0	2	0	0	0	3	0	0	0	3	0	0	0	0	1	0
		(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(2)	(0)
	keratitis	0	0	0	0	1	0	0	0	0	0	0	0	2	0	1	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(2)	(0)
	iritis	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0
		(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)
Harder gl	lymphocytic infiltration	<50>				<50>				<50>				<50>			
		0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0
		(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.02mg/m3				0.2mg/m3				2mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Musculoskeletal system}																	
bone		<50>				<50>				<50>				<50>			
	osteosclerosis	11	3	0	0	14	1	2	0	18	0	0	0	16	3	0	0
		(22)	(6)	(0)	(0)	(28)	(2)	(4)	(0)	(36)	(0)	(0)	(0)	(32)	(6)	(0)	(0)
{Body cavities}																	
pleura		<50>				<50>				<50>				<50>			
	inflammation	0	0	0	0	1	0	1	0	1	0	0	0	1	0	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	fibrosis:focal	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	simple hyperplasia:mesothelium	3	0	0	0	2	0	0	0	6	0	0	0	10	0	0	0
		(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(20)	(0)	(0)	(0)
	deposit of fiber	0	0	0	0	0	0	0	0	7	0	0	0 *	28	0	0	0 **
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(14)	(0)	(0)	(0)	(56)	(0)	(0)	(0)
mediastinum		<50>				<50>				<50>				<50>			
	inflammatory infiltration	17	0	0	0	17	1	0	0	16	0	0	0	19	0	0	0
		(34)	(0)	(0)	(0)	(34)	(2)	(0)	(0)	(32)	(0)	(0)	(0)	(38)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P 0.05 ** : P 0.01 Test of Chi Square

TABLE Q1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR : MALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Integumentary system/appandage}						
subcutis	metastasis:adrenal tumor		<50> 0	<50> 1	<50> 0	<50> 0
{Respiratory system}						
nasal cavit	leukemic cell infiltration		<50> 1	<50> 1	<50> 0	<50> 2
trachea	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
lung	leukemic cell infiltration		<50> 2	<50> 3	<50> 4	<50> 2
	metastasis:peritoneum tumor		0	1	0	0
	metastasis:bone tumor		1	0	0	0
	metastasis:unidentified organ/tissue tumor		0	1	0	0
	metastasis:kidney tumor		0	0	1	0
	metastasis:mediastinum tumor		1	0	0	0
{Hematopoietic system}						
bone marrow	leukemic cell infiltration		<50> 0	<50> 1	<50> 2	<50> 1
	metastasis:liver tumor		1	0	0	0
lymph node	leukemic cell infiltration		<50> 3	<50> 1	<50> 3	<50> 1

< a > a : Number of animals examined at the site
 b b : Number of animals with lesion

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Hematopoietic system}						
lymph node	metastasis:liver tumor		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:peritoneum tumor		0	1	0	0
	metastasis:bone tumor		1	0	0	0
spleen	metastasis:liver tumor		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:pleura tumor		0	1	0	0
{Circulatory system}						
heart	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 1
{Digestive system}						
stomach	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
large intes	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
liver	leukemic cell infiltration		<50> 4	<50> 2	<50> 2	<50> 3
pancreas	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	metastasis:retroperitoneum tumor		1	0	0	0
{Urinary system}						
kidney	leukemic cell infiltration		<50> 2	<50> 2	<50> 4	<50> 1

< a > a : Number of animals examined at the site
 b b : Number of animals with lesion

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Urinary system}						
kidney	metastasis:bone tumor		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:retroperitoneum tumor		1	0	0	0
urin bladd	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
{Endocrine system}						
pituitary	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 2
adrenal	leukemic cell infiltration		<50> 2	<50> 0	<50> 1	<50> 2
	metastasis:bone tumor		1	0	0	0
{Reproductive system}						
testis	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
	metastasis:peritoneum tumor		0	2	1	1
epididymis	metastasis:peritoneum tumor		<50> 0	<50> 3	<50> 1	<50> 1
prostate	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 1
{Nervous system}						
brain	leukemic cell infiltration		<50> 1	<50> 0	<50> 2	<50> 2

< a > a : Number of animals examined at the site
 b : Number of animals with lesion

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Nervous system}						
spinal cord	leukemic cell infiltration		<50> 1	<50> 0	<50> 2	<50> 1
{Musculoskeletal system}						
muscle	metastasis:pleura tumor		<50> 0	<50> 1	<50> 0	<50> 0
bone	metastasis:pleura tumor		<50> 0	<50> 1	<50> 0	<50> 0
{Body cavities}						
pleura	metastasis:bone tumor		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:lung tumor		0	0	0	1
	metastasis:retroperitoneum tumor		1	0	0	0
	metastasis:mediastinum tumor		1	0	0	0
mediastinum	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 1
	metastasis:liver tumor		1	0	0	0
	metastasis:bone tumor		1	0	0	0
	metastasis:lung tumor		0	0	0	1
	metastasis:pleura tumor		0	1	0	0
peritoneum	metastasis:retroperitoneum tumor		<50> 1	<50> 0	<50> 0	<50> 0

< a > a : Number of animals examined at the site
b : Number of animals with lesion

TABLE Q2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR : FEMALE

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Respiratory system}						
nasal cavit	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
lung	leukemic cell infiltration		<50> 6	<50> 8	<50> 8	<50> 5
	metastasis:uterus tumor		2	0	2	1
	metastasis:thyroid tumor		0	1	0	0
	metastasis:subcutis tumor		0	0	1	0
{Hematopoietic system}						
bone marrow	leukemic cell infiltration		<50> 2	<50> 3	<50> 2	<50> 4
lymph node	leukemic cell infiltration		<50> 4	<50> 1	<50> 2	<50> 1
	metastasis:uterus tumor		0	0	0	1
spleen	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0
	metastasis:uterus tumor		1	0	0	1
{Circulatory system}						
heart	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 1
{Digestive system}						
salivary gl	metastasis:mammary gland tumor		<50> 0	<50> 0	<50> 0	<50> 1

< a > a : Number of animals examined at the site
 b : Number of animals with lesion

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Digestive system}						
stomach	metastasis:uterus tumor		<50> 1	<50> 0	<50> 0	<50> 1
liver	leukemic cell infiltration		<50> 6	<50> 6	<50> 11	<50> 8
	metastasis:uterus tumor		1	0	0	1
pancreas	leukemic cell infiltration		<50> 1	<50> 1	<50> 1	<50> 1
	metastasis:uterus tumor		1	0	1	1
	metastasis:peritoneum tumor		0	0	1	0
{Urinary system}						
kidney	leukemic cell infiltration		<50> 2	<50> 2	<50> 5	<50> 1
	metastasis:uterus tumor		0	0	1	1
urin bladd	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
	metastasis:uterus tumor		1	0	0	0
{Endocrine system}						
pituitary	leukemic cell infiltration		<50> 2	<50> 0	<50> 3	<50> 1
	metastasis:subcutis tumor		0	0	1	0

< a > a : Number of animals examined at the site
 b b : Number of animals with lesion

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Endocrine system}						
adrenal	leukemic cell infiltration		<50> 4	<50> 2	<50> 3	<50> 6
{Reproductive system}						
ovary	leukemic cell infiltration		<50> 2	<50> 1	<50> 1	<50> 2
	metastasis:uterus tumor		2	0	2	1
uterus	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 0
mammary gl	leukemic cell infiltration		<50> 1	<50> 1	<50> 0	<50> 0
{Nervous system}						
brain	leukemic cell infiltration		<50> 1	<50> 2	<50> 2	<50> 1
	metastasis:pituitary tumor		0	1	0	0
spinal cord	leukemic cell infiltration		<50> 1	<50> 2	<50> 2	<50> 1
periph nerv	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0
{Special sense organs/appendage}						
Harder gl	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0

< a > a : Number of animals examined at the site
 b b : Number of animals with lesion

STUDY NO. : 0800
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.02mg/m3 50	0.2mg/m3 50	2mg/m3 50
{Musculoskeletal system}						
cartilage	metastasis:uterus tumor		<50> 0	<50> 0	<50> 1	<50> 0
{Body cavities}						
pleura	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	0	1	1
	metastasis:lung tumor		0	0	0	1
mediastinum	leukemic cell infiltration		<50> 1	<50> 1	<50> 0	<50> 1
	metastasis:uterus tumor		<50> 1	<50> 0	<50> 2	<50> 1
peritoneum	metastasis:uterus tumor		<50> 1	<50> 0	<50> 2	<50> 1
< a >	a : Number of animals examined at the site					
b	b : Number of animals with lesion					

TABLE R1

CAUSE OF DEATH : MALE

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
Number of Dead and Moribund Animal	14	8	12	13
no microscop confirm	1	1	1	0
urinary sy les	1	0	1	1
deglutition disorder	0	1	2	3
tumor d:leukemia	2	1	3	2
tumor d:skin/app	0	1	0	0
tumor d:subcutis	0	2	2	0
tumor d:spleen	0	0	0	1
tumor d:oral cavity	0	0	1	0
tumor d:small intes	1	0	0	0
tumor d:liver	1	0	0	0
tumor d:kidney	0	0	1	0
tumor d:pituitary	3	1	1	4
tumor d:brain	0	1	0	0
tumor d:spinal cord	0	0	0	1
tumor d:Zymbal gl	1	0	0	0
tumor d:muscle	1	0	0	0
tumor d:bone	1	0	0	0
tumor d:mediastinum	1	0	0	0
tumor d:retroperit	1	0	0	1

TABLE R2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0800
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	0.02mg/m3	0.2mg/m3	2mg/m3
Number of Dead and Moribund Animal	8	16	11	14
no microscop confirm	0	0	0	2
body cavity lesion	0	1	0	0
deglutition disorder	2	3	1	3
tumor d:leukemia	4	6	6	5
tumor d:subcutis	0	1	0	1
tumor d:kidney	0	0	0	1
tumor d:pituitary	0	4	2	1
tumor d:uterus	2	0	2	1
tumor d:mammary gl	0	1	0	0